Archive for February, 2013

MissionIR Engaged by Chanticleer Holdings (HOTR) for Social Media Relations Services

ATLANTA, GA — (Marketwire) — 02/11/13 — MissionIR, a network partner of DreamTeamGroup (DTG), today announces that they have been retained by Chanticleer Holdings, Inc. (NASDAQ: HOTR) to implement a strategic digital and social media investor relations campaign. Through a network of investor-oriented sites and a full suite of investor awareness services, MissionIR develops and executes investor awareness plans for companies in the small-cap markets.

In addition to fully optimizing Chanticleer’s social media accounts and enhancing outreach strategies already in place, MissionIR will expand the company’s presence among the online investment community with ongoing blogs, articles, newsletter placements, and execution of various social networking strategies and restaurant promotions. Additionally, investor presentation materials are being revamped and then converted to a unique digital publication format with advanced sharing features and multi-platform support.

To connect with Chanticleer via Facebook, please visit http://Facebook.com/ChanticleerHOTR

To connect with Chanticleer via Twitter, please visit http://Twitter.com/ChanticleerHOTR

“Chanticleer’s team has been doing an exceptional job expanding the HOOTERS® restaurant brand to emerging international markets,” stated Sherri Snyder, Director of Marketing at MissionIR. “The areas being targeted offer strong market dynamics with compelling economic growth rates. Chanticleer is well positioned for continued expansion overseas with its turn-key franchise model.”

Chanticleer has rights to develop and operate restaurants in South Africa, Hungary, and parts of Brazil, and has joint ventured with the current franchisee in Australia. Capitalizing on a globally recognized brand in underpenetrated international markets with proven market success, Chanticleer aims to achieve consistent, above-average growth rates and favorable financial returns for its shareholders. For additional information, visit www.HOTR.MissionIR.com.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we’ve done for hundreds of others. Whether it is capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients.

For more information, visit www.MissionIR.com

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements regarding future events and financial performance. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “except,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of these terms and other comparable terminology. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond control. There are or may be important factors that could cause actual results to materially differ from historical results or from any future results expressed or implied by such forward looking statements.

Contact:

Mission Investor Relations
Atlanta, Georgia
www.MissionIR.com
404-941-8975

Monday, February 11th, 2013 Uncategorized Comments Off on MissionIR Engaged by Chanticleer Holdings (HOTR) for Social Media Relations Services

Palatin (PTN) To Report Fiscal Year 2013

CRANBURY, N.J., Feb. 8, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE-MKT: PTN) will announce its second quarter, fiscal year 2013 financial results on Thursday, February 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 14, 2013, which will include discussion of the results of operations in greater detail and an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call / Webcast

– 2Q Fiscal Year 2013 Financial Results Press Release

2/14/2013 at 7:30 a.m. ET

– 2Q Fiscal Year 2013 Conference Call-Live

2/14/2013 at 11:00 a.m. ET

Domestic Dial-In Number

1-888-539-3678

International Dial-In Number

1-719-325-2329

Passcode

4795478

– 2Q Fiscal Year 2013 Conference Call-Replay

2/14/2013-2/21/2013

Domestic Dial-In Number

1-888-203-1112

International Dial-In Number

1-719-457-0820

Passcode

4795478

Webcast Live and Replay Access

Home

The webcast and replay can be accessed by logging on to the “Investor/Media Center-Webcasts” section of Palatin’s website at http://www.palatin.com

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.

Friday, February 8th, 2013 Uncategorized Comments Off on Palatin (PTN) To Report Fiscal Year 2013

Giga-tronics (GIGA) Reports Third Quarter FY 2013 Results

SAN RAMON, Calif., Feb. 8, 2013 (GLOBE NEWSWIRE) — Giga-tronics Incorporated (Nasdaq:GIGA) reported today a net loss of $865,000 or $0.17 per fully diluted share for the quarter ended December 29, 2012. This compares with a net loss of $2,613,000 or $0.52 per fully diluted share for the comparable period a year ago. Net sales increased 41% to $3,946,000 in the third quarter of fiscal 2013 compared to $2,799,000 in the third quarter of fiscal 2012. Gross margin increased by $2,074,000 over the same quarter last year. Operating expenses increased 15% or $323,000 in the third quarter of fiscal 2013 over fiscal 2012 primarily due to a $434,000 (or 58%) increase in product development expenses to invest in new instrument products and expenses associated with a previously announced restructuring totaling $99,000, which were partially offset by reduced selling, general, and administrative expenses. Orders decreased 10% in the third quarter of fiscal 2013 to $2,247,000 from $2,500,000 for the third quarter of fiscal 2012. The decrease in orders is primarily related to a decrease in switch orders which is a business characterized by large periodic orders.

Net loss for the nine month period ended December 29, 2012 was $2,636,000 or $0.52 per fully diluted share. This compares with a net loss of $3,952,000 or $0.79 per fully diluted share for the comparable period a year ago. Net sales increased 10% to $11,409,000 in the first nine months of fiscal 2013 compared to $10,382,000 in the first nine months of fiscal 2012. Gross margin increased by $2,012,000 over the comparable period last year. Operating expenses increased 11% or $692,000 in the first nine months of fiscal 2013 over fiscal 2012 primarily due to a $1,099,000 increase (or 53%) in product development expenses to more aggressively invest in new instrument products and expenses associated with a restructuring totaling $283,000 . Orders increased 40% in the first nine months of fiscal 2013 to $14,745,000 from $10,513,000 for the first nine months of fiscal 2012. The increase in orders is primarily related to orders received from the U.S. government and from prime contractors.

Backlog at December 29, 2012 was $7.2 million (approximately $6.1 million shippable within one year) as compared to $3.8 million (approximately $3.8 million shippable within one year) at December 31, 2011.

Cash and cash equivalents at December 29, 2012 were $2,421,000 compared to $2,096,000 as of September 29, 2012 and $2,365,000 at March 31, 2012.

Mr. John Regazzi, the Company’s CEO stated, “The operating losses for the third quarter and the first nine months of fiscal 2013 reflect our continued commitment to investing in new product development. Nearly half of the reported operating loss is due to these expenses, which we believe are necessary in order to position the Company to achieve future revenue growth and profitability.”

Mr. Regazzi continued, “The balance of the reported loss is the result of insufficient sales volume relative to our fixed infrastructure. To address this issue, the company has committed to combining its Microsource division within its San Ramon headquarters to achieve greater capacity utilization and efficiencies. The move continues on schedule towards a May 1, 2013 completion date with projected benefits of both significant future cost savings and better alignment of our infrastructure costs with anticipated sales volume.”

Mr. Regazzi concluded, “This has been a challenging period as we turn the Company’s primary focus toward new high performance synthesizer markets. We have restructured the management team, worked continuously towards reducing future expenses, and invested in a significant new product program all at the same time. I believe we will begin to see the benefits of these changes starting in May 2013 with improved gross margins following the relocation of the Microsource division and I anticipate Giga-tronics will return to profitability following the introduction of the new microwave product in fiscal 2014.”

Giga-tronics will host a conference call today at 4:30 p.m. ET to discuss the third quarter results. To participate in the call, dial (855) 410-0553 or (646) 583-7389 and enter PIN Code 169920#. The call will also be broadcast over the internet at www.gigatronics.com under “Investor Relations”. The conference call discussion reflects management’s views as of February 8, 2013 only.

Giga-tronics is a publicly held company, traded on the NASDAQ Capital Market under the symbol “GIGA”. Giga-tronics produces instruments, subsystems and sophisticated microwave components that have broad applications in defense electronics, aeronautics and wireless telecommunications.

The Giga-tronics Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6087

This press release contains forward-looking statements concerning profitability, backlog, shipments, revenue growth, improved gross margins, timing of move, and projected savings. Actual results may differ significantly due to risks and uncertainties, such as future orders, cancellations or deferrals, disputes over performance, the ability to collect receivables and general market conditions. For further discussion, see Giga-tronics’ most recent annual report on Form 10-K for the fiscal year ended March 31, 2012, Part I, under the heading “Certain Factors Which May Adversely Affect Future Operations or an Investment in Giga-tronics” and Part II, under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

GIGA-TRONICS INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands except share data) December 29, 2012 March 31, 2012
Assets
Current assets:
Cash and cash-equivalents $ 2,421 $ 2,365
Trade accounts receivable, net of allowance of $53 and $96, respectively 1,776 1,270
Inventories, net 4,151 4,700
Prepaid expenses and other current assets 294 328
Total current assets 8,642 8,663
Property and equipment, net 667 611
Other assets 16
Total assets $ 9,309 $ 9,290
Liabilities and shareholders’ equity
Current liabilities:
Line of credit $ 975 $ —
Accounts payable 805 613
Accrued commission 88 129
Accrued payroll and benefits 776 739
Accrued warranty 137 210
Deferred revenue 1,263 7
Deferred rent 76 59
Capital lease obligations 64 20
Other current liabilities 312 318
Total current liabilities 4,496 2,095
Long term obligations – deferred rent 365 433
Long term obligations – capital lease 106 15
Total liabilities 4,967 2,543
Commitments
Shareholders’ equity:
Preferred stock of no par value;
Authorized – 1,000,000 shares
Series A – designated 250,000 shares; 0 shares at December 29, 2012 and March 31, 2012 issued and outstanding
Series B – designated 10,000 shares; 9,997 shares at December 29, 2012 and March 31, 2012 issued and outstanding; (liquidation preference of $2,309) 1,997 1,997
Common stock of no par value;
Authorized – 40,000,000 shares; 5,029,747 shares at December 29, 2012 and March 31, 2012 issued and outstanding 15,053 14,822
Accumulated deficit (12,708) (10,072)
Total shareholders’ equity 4,342 6,747
Total liabilities and shareholders’ equity $ 9,309 $ 9,290
GIGA-TRONICS INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
Three Month Periods Ended Nine Month Periods Ended
(In thousands except per share data) December 29,
2012
December 31,
2011
December 29,
2012
December 31,
2011
Net sales $ 3,946 $ 2,799 $ 11,409 $ 10,382
Cost of sales 2,342 3,269 6,892 7,877
Gross margin 1,604 (470) 4,517 2,505
Operating expenses:
Engineering 1,179 745 3,159 2,060
Selling, general and administrative 1,187 1,397 3,703 4,393
Restructuring 99 283
Total operating expenses 2,465 2,142 7,145 6,453
Operating loss (861) (2,612) (2,628) (3,948)
Interest expense, net (4) (1) (6) (2)
Loss before income taxes (865) (2,613) (2,634) (3,950)
Provision for income taxes 2 2
Net loss $ (865) $ (2,613) $ (2,636) $ (3,952)
Loss per share – basic $ (0.17) $ (0.52) $ (0.52) $ (0.79)
Loss per share – diluted $ (0.17) $ (0.52) $ (0.52) $ (0.79)
Weighted average shares used in per share calculation:
Basic 5,029 5,024 5,029 5,008
Diluted 5,029 5,024 5,029 5,008
CONTACT: Frank Romejko
         Vice President of Finance / Interim Chief Financial Officer
         (925) 302-1014

company logo

Friday, February 8th, 2013 Uncategorized Comments Off on Giga-tronics (GIGA) Reports Third Quarter FY 2013 Results

Syntroleum (SYNM) Asserts Singapore Patent Against Neste

TULSA, Okla., Feb. 8, 2013 (GLOBE NEWSWIRE) — On February 7, 2013, Syntroleum Corporation (Nasdaq:SYNM) filed suit against Neste Oil Singapore Pte Ltd with the High Court of Singapore asserting its Singapore Patent No. 172,045 entitled “Even Carbon Number Paraffin Composition And Method of Manufacturing Same.” In the court filing, Syntroleum alleges that Neste’s “operation at its renewable diesel refinery in Singapore involves the processing of a bio-renewable feedstock to produce a hydrocarbon composition having at least 75 wt % even carbon number paraffins” which Syntroleum alleges “is claimed at the very least, in claim 22 of the Patent.” Syntroleum’s patent issued on November 15, 2012, and expires on December 10, 2028.

Syntroleum’s action against Neste is not the first dispute between the parties. In May 2012, Neste Oil Oyj sued Syntroleum for alleged infringement of Neste’s U.S. Patent No. 8,187,344. On January 31, 2013, the United States District Court for the District of Delaware granted Syntroleum’s motion to stay Neste’s lawsuit pending reexamination of the ‘344 patent by the U.S. Patent & Trademark Office (USPTO). Previously, the USPTO had granted Syntroleum’s inter partes reexamination request and issued a September 14, 2012 Office Action initially rejecting all claims of the ‘344 patent as obvious in view of the prior art. The ‘344 patent is related to and shares the same inventors as a prior Neste patent (U.S. Patent No. 7,279,018), and both are directed to a fuel composition for diesel engines. The USPTO’s recent Order is consistent with a prior finding on March 22, 2012 by the USPTO’s Board of Patent Appeals and Interferences affirming the Examiner’s rejection of the ‘018 patent’s claims. Neste declined to appeal that ruling and on July 31, 2012, the USPTO issued a Reexamination Certificate canceling all claims of the ‘018 patent. The reexamination proceedings involving the ‘344 patent remain pending.

Syntroleum continues to defend a second suit filed by Neste on December 20, 2012 in the District of Delaware alleging patent infringement of U.S. Patent No. 8,212,094. The ‘094 patent covers similar subject matter and shares a common inventor with Neste’s ‘018 and ‘344 patents. Syntroleum denies Neste’s claims and will continue to vigorously defend against the Neste patents and is confident that its position will be vindicated.

Syntroleum has invested substantial time and resources in its proprietary Bio-Synfining® technology and will likewise seek to enforce its intellectual property rights in venues around the world.

About Syntroleum (Nasdaq:SYNM)

Syntroleum Corporation owns the Syntroleum® Process for Fischer-Tropsch (FT) conversion of synthesis gas into liquid hydrocarbons, the Synfining® Process for upgrading FT liquid hydrocarbons into refined petroleum products, and the Bio-Synfining® technology for converting renewable feedstocks into drop-in fuels.  Syntroleum has a 50% interest in Dynamic Fuels, LLC, which operates a 75 million gallon per year renewable fuels facility located in Geismar, Louisiana utilizing its Bio-Synfining® technology.   For additional information, visit the Company’s web site at www.syntroleum.com.

The Syntroleum Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5984

This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical facts. These forward‑looking statements may include statements relating to the Fischer-Tropsch (“FT”) Process, Syntroleum® Process, the Synfining® Process, and related technologies including, gas-to-liquids (“GTL”), coal-to-liquids (“CTL”), and biomass-to-liquids (“BTL”), our renewable fuels Bio-Synfining® Technology, plants based on the Syntroleum® Process and/or Bio-Synfining®, anticipated costs to design, construct and operate these plants, the time of commencement and completion of the design and construction of these plants, expected production of fuel, obtaining required financing for these plants and our other activities, the economic construction and operations of Fischer-Tropsch (“FT”) and/or Bio-Synfining® plants, the value and markets for products, testing, certification, characteristics and use of Plant products, the continued development of the Syntroleum® Process and Bio-Synfining® Technology and the anticipated capital expenditures, expense reductions, cash outflows, expenses, use of proceeds from out equity offerings, anticipated revenues, availability of catalyst, our support of and relationship with our licensees, and any other forward-looking statements including future growth, cash needs, capital availability, operations, business plans and financial results. When used in this document, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should” and similar expressions are intended to be among the statements that identify forward‑looking statements. Although we believe that the expectations reflected in these forward‑looking statements are reasonable, these kinds of statements involve risks and uncertainties. Actual results may not be consistent with these forward‑looking statements. Syntroleum undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time. Important factors that could cause actual results to differ from these forward-looking statements are described under “Item 1A. Risk Factors” and elsewhere in our 2011 Annual Report on Form 10K.

® “Syntroleum” is registered as a trademark and service mark in the U.S. Patent and Trademark Office.

CONTACT: Ron Stinebaugh
         Syntroleum Corporation
         (281) 224-9862
         www.syntroleum.com

company logo

Friday, February 8th, 2013 Uncategorized Comments Off on Syntroleum (SYNM) Asserts Singapore Patent Against Neste

Carver Bancorp (CARV) Reports Third Quarter Fiscal Year 2013 Results

NEW YORK, Feb. 8, 2013 (GLOBE NEWSWIRE) — Carver Bancorp, Inc. (the “Company”) (Nasdaq:CARV), the holding company for Carver Federal Savings Bank (“Carver” or the “Bank”), today announced financial results for its third fiscal quarter of 2013 ended December 31, 2012 (“Fiscal 2013”).

The Company reported net income of $0.5 million or an earnings per share of $0.13 for the third quarter of Fiscal 2013, compared to a net loss of $0.7 million or a loss per share of $0.26, for the prior year period. For the nine months ended December 31, 2012, the Company reported a net loss of $26 thousand or a loss per share of $0.01, compared to a net loss of $16.3 million or a loss per share of $16.81 for the prior year period.

Deborah C. Wright, Carver Bancorp Chairman and CEO said, “We are pleased to report our first quarterly profit since our real estate loan portfolio was severely impacted by the economic downturn. Our positive net income results for the quarter bring Carver’s year-to-date results close to break-even. Our loan performance also continued to improve, with non-performing assets declining 5% from the prior quarter and 30% year-to-date. While we have made tremendous progress, additional work still needs to be done to strengthen our loan portfolio.

Ms. Wright added: “We are also encouraged by the ongoing growth and market opportunity for Carver Community Cash. This product line, which was designed to meet the needs of the “unbanked” in our communities, helped contribute to record depository fees and charges for the quarter, which reached nearly $1 million. As we continue to add more services, such as our CashAccess kiosk, a self-service option, we are optimistic that revenues from this product line will continue to grow. Last, our recently announced executive management team expansion and realignment, positions us to further strengthen our new business platform and sets the stage for fiscal 2014 and beyond.”

Statement of Operations Highlights

Third Quarter Results

The Company reported net income for the three months ended December 31, 2012 of $0.5 million compared to a net loss of $0.7 million for the prior year period. The primary drivers of the net income versus the loss in the prior year period were gains on sales of loans held for sale (“HFS”) and a negative loan loss provision in the current quarter versus a build in the prior year.

Net Interest Income

Interest income decreased $1.0 million, or 14.2%, to $5.9 million in the third quarter, compared to the prior year quarter, with the decrease primarily attributed to a $102.5 million, or 20.2%, decrease in average loans. Although the average yield on loans increased 20 basis points to 5.26% from 5.06%, the decrease in average loans reduced total interest income on loans. These conditions will likely continue until average loan balances increase, given lower yields available on alternative earning assets. The average yield on mortgage-backed securities fell 66 basis points to 1.86% from 2.52% during the quarter, as higher yielding securities experienced early payoffs and were replaced with lower yielding securities.

Interest expense decreased $0.7 million, or 34.7%, to $1.2 million for the third quarter, compared to $1.9 million for the prior year quarter, as lower cost deposits replaced borrowings. The average rate on interest bearing liabilities decreased 49 basis points to 0.99% for the quarter ended December 31, 2012.

Provision for Loan Losses

The Company recorded a $0.4 million release of loan loss reserves for the third quarter compared to a $0.1 million provision for the prior year quarter. Net charge-offs of $1.5 million were recognized compared to $1.1 million in the prior year period. Charge-offs to the provision, in both quarters, were primarily related to impaired loans and loans moved to HFS. The impact of the charge-offs to the provision was partially offset by a reduction in the allowance for loan losses following reductions in loss experience and, to a lesser extent, a decline in loan balances.

Non-interest Income

Non-interest income increased $1.9 million, or 359.5%, to $2.5 million for the third quarter, compared to $0.6 million for the prior year quarter. The increase was primarily due to $1.1 million gains on sale of HFS loans and $60 thousand in capital gains on the Company’s investment portfolio. Non-interest income in the prior period was impacted by HFS valuation adjustments of $0.5 million.

Non-interest Expense

Non-interest expense decreased $0.5 million to $7.3 million during the third quarter, compared to $7.8 million in the prior year quarter. Non-interest expense was lower in all categories except data processing with the largest decreases comprised of $0.2 million in compensation expenses and $0.1 million in consulting fees.

Income Taxes

The income tax expense was $68 thousand for the third quarter compared to a benefit of $1.0 million in the prior year period.

Nine Month Results

The Company reported a net loss for the nine months ended December 31, 2012 of $26 thousand compared to a net loss of $16.3 million for the prior year period. This improvement was primarily driven by reductions in the provision for loan losses and certain non-interest expense categories and increases in non-interest income.

Net Interest Income

Interest income decreased $3.4 million, or 15.7%, to $18.2 million in the nine month period, compared to the prior year period, with the decrease primarily attributed to a $129.0 million, or 23.7%, decrease in average loans. The average yield on loans increased 34 basis points to 5.25% from 4.91%, which was directly related to a reduction in non-performing loans. The decline in average loan balances did, however, decrease total interest income on loans. The average yield on mortgage-backed securities fell 76 basis points to 2.03% from 2.79% during the prior year period, as higher yielding securities experienced early payoffs and were replaced with lower yielding securities.

Interest expense decreased $1.8 million, or 32.1%, to $3.8 million for the nine month period, compared to $5.6 million for the prior year period, as lower cost deposits replaced more expensive long-term borrowings. The average rate on interest bearing liabilities decreased 41 basis points to 1.02% for the nine months ended December 31, 2012.

Provision for Loan Losses

The Company recorded a $0.4 million provision for loan losses for the nine month period, compared to $12.3 million for the prior year period. For the nine months ended December 31, 2012 net charge-offs of $5.7 million were recognized compared to $15.0 million in the prior year period. Charge-offs in both periods were primarily related to impaired loans and loans that moved to HFS.

Non-interest Income

Non-interest income increased $3.4 million, or 139.2%, to $5.9 million for the nine month period, compared to $2.5 million for the prior year period. The majority of the increase was attributable to gains on sales of loans, fee income received from a New Market Tax Credit (“NMTC”) transaction and an increase in depository fees. Non-interest income in the prior year period was impacted by HFS valuation adjustments of $0.9 million.

Non-interest Expense

Non-interest expense decreased $1.9 million to $20.8 million, or 8.4% compared to $22.7 million in the prior year period. Non-interest expense was lower in all categories except data processing, with the largest decreases comprised of $0.9 million in compensation expenses and a decline of $0.2 million in FDIC premiums.

Income Taxes

The income tax expense was $264 thousand for the nine month period compared to a benefit of $927 thousand for the prior year period.

Financial Condition Highlights

At December 31, 2012, total assets decreased $0.6 million, or 0.09%, to $640.6 million, compared to $641.2 million at March 31, 2012. The overall change was primarily due to decreases in the loan portfolio of $48.4 million, the allowance for loan losses of $5.3 million and HFS loans of $10.6 million. These decreases were offset by increases in cash and cash equivalents of $30.2 million and $23.3 million in the investment portfolio.

Total securities increased $23.3 million, or 24.2%, to $119.5 million at December 31, 2012, compared to $96.2 million at March 31, 2012. This change reflects an increase of $24.8 million in available-for-sale securities offset by a $1.5 million decrease in held-to-maturity securities, as the Company continues to diversify its investment portfolio to increase interest earning assets.

Total loans receivable decreased $48.4 million, or 11.72%, to $364.5 million at December 31, 2012, compared to $412.9 million at March 31, 2012. The decrease resulted from $50.0 million of principal repayments and loan payoffs across all loan classifications comprised the majority of the decrease, with the largest declines in multi-family, commercial and construction loans. An additional $9.1 million in loans were transferred from held for investment to HFS and $5.7 million in principal charge offs. Decreases were partially offset by loan originations and advances of $17.4 million. The decrease of $5.3 million in the allowance for loan losses is due to stabilization in valuations of the non performing loans and the decrease in loan balances.

HFS loans decreased $10.6 million or 35.9% to $19.0 million as the Company continued to take aggressive steps to resolve troubled loans. During the year, $9.1 million in loans, net of charge-offs, transferred into the held for sale portfolio from the held for investment portfolio. This increase was offset by $19.7 million of sales and paydowns.

Total liabilities increased $0.4 million, or 0.07%, to $585.0 million at December 31, 2012, compared to $584.6 million at March 31, 2012, due to an increase in borrowings of $30.0 million and an increase in other liabilities of $1.4 million partially offset by reductions in deposits of $30.9 million.

Deposits decreased $30.9 million, or 5.81%, to $501.6 million at December 31, 2012, compared to $532.6 million at March 31, 2012, due principally to $10 million of planned withdrawals from non-interest bearing control disbursements accounts and management’s decision to release higher cost certificates of deposit.

Advances from the Federal Home Loan Bank of New York (“FHLB-NY”) and other borrowed money increased $30.0 million, or 69.02%, to $73.4 million at December 31, 2012, compared to $43.4 million at March 31, 2012, as the Company added short-term borrowings during the nine month period to replace previously terminated long-term borrowings.

Total equity decreased $1.0 million, or 1.80%, to $55.6 million at December 31, 2012, compared to $56.6 million at March 31, 2012. The decline reflects a net loss before taxes of $0.9 million (excluding non-controlling interest).

Asset Quality

At December 31, 2012, non-performing assets totaled $57.6 million, or 8.98% of total assets, compared to $86.4 million or 13.47% of total assets at March 31, 2012, and $93.9 million or 14.01% of total assets at December 31, 2011. Non-performing assets at December 31, 2012 were comprised of $12.0 million of loans 90 days or more past due and non-accruing, $18.0 million of loans classified as a troubled debt restructuring, $5.6 million of loans that are either performing or less than 90 days past due that have been classified as impaired, $3.0 million of Real Estate Owned, and $19.0 million of loans classified as HFS.

The allowance for loan losses was $14.5 million at December 31, 2012, which represents a ratio of the allowance for loan losses to non-performing loans of 40.72% compared to 36.31% at March 31, 2012. The ratio of the allowance for loan losses to total loans was 3.97% at December 31, 2012, a decline from 4.80% at March 31, 2012.

About Carver Bancorp, Inc.

Carver Bancorp, Inc. is the holding company for Carver Federal Savings Bank, a federally chartered stock savings bank, founded in 1948 to serve African-American communities whose residents, businesses, and institutions had limited access to mainstream financial services. Carver, the largest African- and Caribbean-American run bank in the United States, operates nine full-service branches in the New York City boroughs of Brooklyn, Manhattan, and Queens. For further information, please visit the Company’s website at www.carverbank.com.

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, risks and uncertainties. More information about these factors, risks and uncertainties is contained in our filings with the Securities and Exchange Commission.

CARVER BANCORP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION
$ in thousands except per share data December 31, March 31,
2012 2012
ASSETS
Cash and cash equivalents:
Cash and due from banks $ 114,292 $ 89,872
Money market investments 7,558 1,825
Total cash and cash equivalents 121,850 91,697
Restricted cash 6,416 6,415
Investment securities:
Available-for-sale, at fair value 109,936 85,106
Held-to-maturity, at amortized cost (fair value of $10,191 and $11,774 at December 31, 2012 and March 31, 2012, respectively) 9,565 11,081
Total investments 119,501 96,187
Loans held-for-sale (“HFS”) 18,991 29,626
Loans receivable:
Real estate mortgage loans 330,655 367,611
Commercial business loans 33,535 43,989
Consumer loans 264 1,258
Loans, net 364,454 412,858
Allowance for loan losses (14,483) (19,821)
Total loans receivable, net 349,971 393,037
Premises and equipment, net 8,885 9,573
Federal Home Loan Bank of New York (“FHLB-NY”) stock, at cost 3,368 2,168
Accrued interest receivable 2,359 2,256
Other assets 9,297 10,271
Total assets $ 640,638 $ 641,230
LIABILITIES AND STOCKHOLDERS’ EQUITY
LIABILITIES:
Deposits:
Savings 96,226 101,079
Non-Interest Bearing Checking 61,676 67,202
NOW 25,044 28,325
Money Market 113,417 109,404
Certificates of Deposit 205,286 226,587
Total Deposits 501,649 532,597
Advances from the FHLB-New York and other borrowed money 73,403 43,429
Other liabilities 9,986 8,585
Total liabilities 585,038 584,611
Stockholders’ equity:
Preferred stock, (par value $0.01, per share), 45,118 Series D shares, with a liquidation preference of $1,000 per share, issued and outstanding 45,118 45,118
Common stock (par value $0.01 per share: 10,000,000 shares authorized; 3,697,264 issued; 3,695,320 and 3,695,174 shares outstanding at December 31, 2012 and March 31, 2012, respectively) 61 61
Additional paid-in capital 55,574 54,068
Accumulated deficit (45,125) (45,091)
Non-controlling interest 95 2,751
Treasury stock, at cost (1,944 shares at December 31, 2012 and 2,090 and March 31, 2012, respectively). (417) (447)
Accumulated other comprehensive loss 294 159
Total stockholders’ equity 55,600 56,619
Total liabilities and stockholders equity $ 640,638 $ 641,230
CARVER BANCORP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended Nine Months Ended
$ in thousands except per share data December 31, December 31,
2012 2011 2012 2011
Interest Income:
Loans $ 5,325 $ 6,416 $ 16,398 $ 20,076
Mortgage-backed securities 215 279 783 1,018
Investment securities 349 114 857 340
Money market investments 38 102 156 151
Total interest income 5,927 6,911 18,194 21,585
Interest expense:
Deposits 868 1,069 2,750 3,012
Advances and other borrowed money 342 785 1,033 2,560
Total interest expense 1,210 1,854 3,783 5,572
Net interest income 4,717 5,057 14,411 16,013
Provision for loan losses (398) 113 386 12,290
Net interest income after provision for loan losses 5,115 4,944 14,025 3,723
Non-interest income:
Depository fees and charges 964 740 2,652 2,212
Loan fees and service charges 170 203 565 689
Gain on sale of securities, net 60 60
Gain on sales of loans, net 1,109 19 1,714 154
Loss on real estate owned (91) (288) (216)
New Market Tax Credit (“NMTC”) fees 625
Lower of Cost or market adjustment on loans held for sale (530) (905)
Other 238 212 587 539
Total non-interest income 2,541 553 5,915 2,473
Non-interest expense:
Employee compensation and benefits 2,819 3,006 8,243 9,188
Net occupancy expense 910 903 2,684 2,805
Equipment, net 314 329 889 1,029
Data processing 326 216 842 596
Consulting fees 63 165 243 370
Federal deposit insurance premiums 320 369 994 1,177
Other 2,552 2,788 6,933 7,531
Total non-interest expense 7,304 7,776 20,828 22,696
Profit/(Loss) before income taxes 352 (2,279) (888) (16,500)
Income tax expense (benefit) 68 (1,004) 264 (927)
Net income/(loss) before attribution of noncontrolling interest 284 (1,275) (1,152) (15,573)
Non Controlling interest, net of taxes (190) (595) (1,126) 687
Net income/(loss) $ 474 $ (680) $ (26) $ (16,260)
Earnings/(loss) per common share:
Basic $ 0.13 $ (0.26) $ (0.01) $ (16.81)
Diluted $ 0.13 N/A N/A N/A
CARVER BANCORP, INC. AND SUBSIDIARIES
Non Performing Asset Table
$ in thousands December 2012 September 2012 June 2012 March 2012 December 2011
Loans accounted for on a non-accrual basis (1):
Gross loans receivable:
One- to-four family $ 7,249 $ 6,094 $ 7,363 $ 6,988 $ 12,863
Multi-family 483 1,724 1,790 2,923 2,619
Commercial real estate 18,872 14,145 16,487 24,467 26,313
Construction 1,230 4,258 4,658 11,325 17,651
Business 7,718 8,717 9,337 8,862 9,825
Consumer 14 15 23 4
Total non-performing loans $ 35,566 $ 34,953 $ 39,635 $ 54,588 $ 69,275
Other non-performing assets (2):
Real estate owned $ 2,996 $ 2,119 $ 1,961 $ 2,183 $ 2,183
Loans held for sale 18,991 26,830 30,163 29,626 22,490
Total other non-performing assets 21,987 28,949 32,124 31,809 24,673
Total non-performing assets (3): $ 57,553 $ 63,902 $ 71,759 $ 86,397 $ 93,948
Non-performing loans to total loans 9.76 % 9.20 % 10.17 % 13.22 % 15.12 %
Non-performing assets to total assets 8.98 % 10.01 % 11.13 % 13.47 % 14.01 %
(1) Non-accrual status denotes any loan where the delinquency exceeds 90 days past due and in the opinion of management the collection of contractual interest and/or principal is doubtful. Payments received on a non-accrual loan are either applied to the outstanding principal balance or recorded as interest income, depending on assessment of the ability to collect on the loan.
(2) Other non-performing assets generally represent loans that the Bank is in the process of selling and has designated held for sale or property acquired by the Bank in settlement of loans less costs to sell (i.e., through foreclosure, repossession or as an in-substance foreclosure). These assets are recorded at the lower of their cost or fair value.
(3) Troubled debt restructured loans performing in accordance with their modified terms for less than six months and those not performing in accordance with their modified terms are considered non-accrual and are included in the non-accrual category in the table above. TDR loans that have performed in accordance with their modified terms for a period of at least six months are generally considered performing loans and are not presented in the table above.
CARVER BANCORP, INC. AND SUBSIDIARIES
CONSOLIDATED AVERAGE BALANCES
For the Three Months Ended December 31,
2012 2011
$ in thousands Average Average Average Average
Balance Interest Yield/Cost Balance Interest Yield/Cost
Interest Earning Assets:
Loans (1) $ 404,613 $ 5,325 5.26 % $ 507,153 $ 6,416 5.06 %
Mortgaged-backed securities 46,251 215 1.86 % 44,246 279 2.52 %
Investment securities 73,392 267 1.46 % 24,169 81 1.33 %
Restricted Cash Deposit 6,415 0.03 % 6,397 0.03 %
Equity securities (2) 2,545 23 3.60 % 2,655 30 4.42 %
Other investments and federal funds sold 66,899 97 0.58 % 63,309 105 0.66 %
Total interest-earning assets 600,115 5,927 3.95 % 647,929 6,911 4.27 %
Non-interest-earning assets 9,273 6,921
Total assets $ 609,388 $ 654,850
Interest Bearing Liabilities:
Deposits:
Now demand $ 25,054 10 0.16 % $ 27,191 11 0.16 %
Savings and clubs 97,391 64 0.26 % 102,960 68 0.26 %
Money market 112,044 201 0.71 % 83,690 251 1.19 %
Certificates of deposit 204,609 582 1.13 % 193,358 728 1.49 %
Mortgagors deposits 2,282 11 1.92 % 2,309 11 1.89 %
Total deposits 441,380 868 0.78 % 409,508 1,069 1.04 %
Borrowed money 43,737 342 3.11 % 88,679 785 3.51 %
Total interest-bearing liabilities 485,117 1,210 0.99 % 498,187 1,854 1.48 %
Non-interest-bearing liabilities:
Demand 60,117 84,585
Other liabilities 9,329 8,449
Total liabilities 554,563 591,221
Stockholders’ equity 54,825 63,629
Total liabilities & stockholders’ equity $ 609,388 $ 654,850
Net interest income $ 4,717 $ 5,057
Average interest rate spread 2.96 % 2.79 %
Net interest margin 3.14 % 3.12 %
(1) Includes non-accrual loans
(2) Includes FHLB-NY stock
CARVER BANCORP, INC. AND SUBSIDIARIES
CONSOLIDATED AVERAGE BALANCES
For the Nine Months Ended December 31,
2012 2011
$ in thousands Average Average Average Average
Balance Interest Yield/Cost Balance Interest Yield/Cost
Interest Earning Assets:
Loans (1) $ 416,306 $ 16,398 5.25 % $ 545,267 $ 20,076 4.91 %
Mortgaged-backed securities 51,418 783 2.03 % 48,631 1,018 2.79 %
Investment securities 57,776 599 1.38 % 23,773 218 1.22 %
Restricted Cash Deposit 6,415 1 0.03 % 6,969 2 0.03 %
Equity securities (2) 2,545 70 3.64 % 2,867 111 5.14 %
Other investments and federal funds sold 77,438 343 0.59 % 44,877 160 0.47 %
Total interest-earning assets 611,898 18,194 3.96 % 672,384 21,585 4.28 %
Non-interest-earning assets 8,139 3,015
Total assets $ 620,037 $ 675,399
Interest Bearing Liabilities:
Deposits:
Now demand $ 26,016 31 0.16 % $ 26,451 32 0.16 %
Savings and clubs 99,495 197 0.26 % 105,112 208 0.26 %
Money market 110,241 598 0.72 % 76,232 608 1.06 %
Certificates of deposit 212,432 1,894 1.19 % 198,780 2,135 1.43 %
Mortgagors deposits 2,193 30 1.82 % 2,392 30 1.66 %
Total deposits 450,377 2,750 0.81 % 408,967 3,013 0.98 %
Borrowed money 43,857 1,033 3.13 % 99,806 2,561 3.41 %
Total interest-bearing liabilities 494,234 3,783 1.02 % 508,773 5,574 1.45 %
Non-interest-bearing liabilities:
Demand 62,057 103,069
Other liabilities 8,160 8,162
Total liabilities 564,451 620,004
Stockholders’ equity 55,586 55,395
Total liabilities & stockholders’ equity $ 620,037 $ 675,399
Net interest income $ 14,411 $ 16,011
Average interest rate spread 2.94 % 2.83 %
Net interest margin 3.14 % 3.18 %
(1) Includes non-accrual loans
(2) Includes FHLB-NY stock
CARVER BANCORP, INC. AND SUBSIDIARIES
CONSOLIDATED SELECTED KEY RATIOS
Three Months Ended Nine Months Ended
December 31, December 31,
Selected Statistical Data: 2012 2011 2012 2011
Return on average assets (1) 0.31 % (0.42)% (0.01)% (4.81)%
Return on average equity (2) 3.46 % (4.27)% (0.14)% (58.71)%
Net interest margin (3) 3.14 % 3.12 % 3.14 % 3.19 %
Interest rate spread (4) 2.96 % 2.79 % 2.94 % 2.83 %
Efficiency ratio (5) 100.63 % 138.60 % 102.47 % 122.77 %
Operating expenses to average assets (6) 4.79 % 4.75 % 10.08 % 6.72 %
Average equity to average assets (7) 9.00 % 9.72 % 8.96 % 8.20 %
Average interest-earning assets to average interest-bearing liabilities 1.24 1.17 1.24 1.23
Net income (loss) per share (*) $ 0.13 $ (0.26) $ (0.01) $ (16.81)
Average shares outstanding (*) 3,695,653 2,621,340 3,695,616 984,348
December 31,
2012 2011
Capital Ratios:
Tier 1 leverage ratio (8) 10.06 % 10.30 %
Tier 1 risk-based capital ratio (8) 16.56 % 14.76 %
Total risk-based capital ratio (8) 19.13 % 17.11 %
Asset Quality Ratios:
Non performing assets to total assets (9) 8.98 % 14.01 %
Non performing loans to total loans receivable (9) 9.76 % 15.12 %
Allowance for loan losses to total loans receivable 3.97 % 4.45 %
Allowance for loan losses to non-performing loans 40.72 % 29.46 %
(1) Net income (loss), annualized, divided by average total assets.
(2) Net income (loss), annualized, divided by average total equity.
(3) Net interest income, annualized, divided by average interest-earning assets.
(4) Combined weighted average interest rate earned less combined weighted average interest rate cost.
(5) Operating expenses divided by sum of net interest income plus non-interest income.
(6) Non-interest expenses, annualized, divided by average total assets.
(7) Average equity divided by average assets for the period ended.
(8) These ratios reflect consolidated bank only.
(9) Non performing assets consist of non-accrual loans, and real estate owned
(*) Common stock shares reflect 1 for 15 reverse stock split which was effective on October 27, 2011
CONTACT: Ruth Pachman/Michael Herley
         Kekst and Company
         (212) 521-4800

         David L. Toner
         Carver Bancorp, Inc.
         (718) 676-8936
Friday, February 8th, 2013 Uncategorized Comments Off on Carver Bancorp (CARV) Reports Third Quarter Fiscal Year 2013 Results

Oncolytics Biotech® (ONCY) Announces Additional Positive REOLSYIN® Clinical Trial Data

CALGARY, Feb. 8, 2013 /CNW/ – Oncolytics Biotech Inc. (“Oncolytics”) (TSX: ONC) (NASDAQ: ONCY) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 021).

The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment cycles. Of 20 evaluable patients, 19 (95%) exhibited overall tumour shrinkage, (mean (20 patients): 33.7% shrinkage). A waterfall graph showing individual patient data will be available on the Company’s website at http://www.oncolyticsbiotech.com/presentations.

“It’s exciting to have 95% of patients in this study exhibit tumour shrinkage and these results further suggest that REOLYSIN may have potential use in neoadjuvant (pre-surgical) settings,” said Dr. Brad Thompson, President and CEO of Oncolytics. “Based on these findings we intend to continue to look at REOLYSIN as a treatment for cancers of the lung and cancers that metastasize to the lung.”

The study enrolled patients with metastatic or recurrent squamous cell carcinoma of the lung.  The primary endpoint of the study is objective tumour response rates, and the secondary objectives include progression free survival and overall survival. To date, the Company has observed nine partial responses (PR), nine stable disease (SD) and three progressive disease (PD) by RECIST criteria for a disease control rate (complete response (CR) + PR + SD)) of 86%. The study continues to enroll patients.

About SCC Lung Cancer

The American Cancer Society estimates that in 2013, approximately 228,190 new cases of lung cancer will be diagnosed. Approximately 84% of all lung cancers are classified as non-small cell lung cancer (NSCLC); squamous cell carcinomas account for approximately 25% of all lung cancers. Lung cancer is by far the leading cause of cancer death among both men and women. There will be an estimated 159,480 deaths from lung cancer in the United States in 2012, accounting for around 27% of all cancer deaths. More people die of lung cancer than from colon, breast, and prostate cancers combined. For more information about SCC lung cancer, please go to www.cancer.org.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics’ clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as, the Company’s expectations related to the Phase II squamous cell carcinoma of the lung trial of REOLYSIN in combination with carboplatin and paclitaxel, and the Company’s belief as to the potential of REOLYSIN as a cancer therapeutic, and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statement and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.

SOURCE: Oncolytics Biotech Inc.

The Equicom Group
Nick Hurst
300 5th Ave. SW, 10th Floor
Calgary, Alberta, T2P 3C4
Tel: 403.218.2835
Fax: 403.218.2830
nhurst@tmxequicom.com

Dian Griesel, Inc.
Susan Forman
396 West Broadway, 2nd Floor
New York, NY  10012
Tel:  212.825.3210
Fax:  212.825.3229
sforman@dgicomm.com

Friday, February 8th, 2013 Uncategorized Comments Off on Oncolytics Biotech® (ONCY) Announces Additional Positive REOLSYIN® Clinical Trial Data

Pacer International (PACR) Reports Fourth Quarter Results

Pacer International, Inc. (Nasdaq: PACR), the asset-light North American freight transportation and logistics services provider, today reported financial results for the three-month period and the year ended December 31, 2012.

FOURTH QUARTER RESULTS

  • Income from operations increased 9.0%, excluding the impact of realignment expense of $0.8 million and $0.3 million in 2012 and 2011, respectively. Intermodal income from operations increased $2.3 million and logistics income from operations decreased $1.4 million;
  • Earnings per share improved by $0.03 to $0.06 in 2012. Excluding the effect of the 2012 realignment expense of $0.02 per share, earnings per share was $0.08 in 2012;
  • Intermodal revenues improved by $7.2 million or 2.5% while logistics revenues declined by 16.1% to $57.3 million. Total revenues decreased by 1.7% to $351.9 million;
  • Intermodal gross margin improved by $2.7 million and logistics gross margin declined by $2.5 million. Total gross margin percentage increased by 20 basis points;
  • Net income increased $1.1 million to $2.2 million;
  • Cash provided by operating activities increased by $2.9 million or 40.8%, from $7.1 million in the fourth quarter of 2011 to $10.0 million in the fourth quarter of 2012.

(In millions, except for per share data)

2012 2011
Q1 Q2 Q3 Q4 Q4
Revenue $ 345.9 $ 368.3 $ 348.9 $ 351.9 $ 358.0
Gross margin $ 31.9 $ 32.4 $ 31.7 $ 35.9 $ 35.7
Gross margin % 9.2 % 8.8 % 9.1 % 10.2 % 10.0 %
SG&A $ 31.9 $ 29.9 $ 29.6 $ 32.0 $ 31.5
Income from operations 2.5 2.3 4.1 4.2
Net income (loss) (0.3 ) 1.3 1.1 2.2 1.1
Earnings (loss) per share $ (0.01 ) $ 0.04 $ 0.03 $ 0.06 $ 0.03

“The quarter was much improved from the previous three as we were focused on improving under-performing traffic corridors and reducing controllable costs to help offset rising external purchased transportation costs. We are also excited about the new opportunities created by our new cross border auto agreement with the Union Pacific. We will pursue automotive parts shipments as a retail provider of door-to-door intermodal services and continue the development of our east-west intermodal business to grow our intermodal segment,” said Daniel W. Avramovich, Chairman and Chief Executive Officer.

“We recently implemented a realignment within our intermodal business. The new alignment will increase organizational focus on our retail intermodal and related services, enhance the service we provide to our customers and allow us to focus on delivering consistent and improved financial results,” said Paul Svindland, Chief Operating Officer.

“It was a good quarter as both our consolidated net income and gross margin improved year over year. We believe the actions we have taken to combat competitive pricing environments and rising rail costs have positioned us well going forward. We also believe the talented people joining our logistics segment and the new business licenses obtained in China will help us continue to improve our future performance,” said John J. Hafferty, Chief Financial Officer.

ANNUAL RESULTS

  • Income from operations decreased $18.1 million. Income from operations in the intermodal segment, excluding from 2011 results the gain on sale of railcar assets of $4.7 million and the $7.3 million impact of the previously announced reduction in volume from an ocean carrier customer, increased year over year by $1.8 million. Total intermodal income from operations decreased $10.2 million and logistics income from operations decreased $8.2 million;
  • Earnings per share decreased from $0.40 in the 2011 period to $0.12 in the 2012 period;
  • Selling, general and administrative expenses decreased by $8.4 million year over year;
  • Intermodal revenues improved by $4.3 million or 0.4%. Excluding the impact from the reduction in volume from an ocean carrier customer of $76.5 million in 2011, intermodal revenues increased by 7.4% to $1,179.6 million. Logistics revenues declined by 21.5% to $238.3 million. Overall, revenues decreased by 4.3% to $1,415.0 million;
  • Intermodal gross margin declined by $10.4 million. Excluding the impact from the reduction in volume from the ocean carrier customer, intermodal gross margin decreased by $3.1 million. Logistics gross margin declined by $11.7 million;
  • Net income decreased $9.6 million to $4.3 million.

(In millions, except for per share data)

2012 2011
Revenue $ 1,415.0 $ 1,478.5
Gross margin $ 131.9 $ 154.0
Gross margin % 9.3 % 10.4 %
SG&A $ 123.4 $ 131.8
Income from operations 8.9 27.0
Net income 4.3 13.9
Earnings per share $ 0.12 $ 0.40

A tabular reconciliation detailing the adjustments made to arrive at the adjusted financial results set forth above and elsewhere in this press release from financial results determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”) is contained in the reconciliation schedules attached to this press release.

Certain reclassifications have been made to the 2011 operating expenses in order to conform to the 2012 presentation. The reclassifications had no impact on previously reported income. A tabular reconciliation detailing the reclassification amounts for 2011 is contained in the schedules attached to this press release.

2013 GUIDANCE

We are reconfirming our 2013 guidance and we expect earnings per share in 2013 to range between $0.25 and $0.35.

CONFERENCE CALL TODAY Pacer International will hold a conference call for investors, analysts, business and trade media, and other interested parties at 8:30 a.m. EST, today (Thursday, February 7, 2013). To participate, please call five minutes early by dialing (800) 230-1074 (in USA) and ask for “Pacer International Fourth Quarter Earnings Call.” International callers can dial (612) 234-9960.

An audio-only, simultaneous Webcast of the live conference call can be accessed through the Investors link on the company’s website at www.pacer.com. For persons unable to participate in either the conference call or the Webcast, a digitized replay will be available from February 7, 2013 at 11:00 a.m. EST to March 7, 2013 at 11:59 p.m. EST. For the replay, dial (800) 475-6701(USA) or (320) 365-3844 (international), using access code 278889. During such period, the replay also can be accessed through the Investors link on the company’s website at www.pacer.com

ABOUT PACER INTERNATIONAL (www.pacer.com)

Pacer International, a leading asset-light North American freight transportation and logistics services provider, offers a broad array of services to facilitate the movement of freight from origin to destination through its intermodal and logistics operating segments. The intermodal segment offers container capacity, integrated local transportation services, and door-to-door intermodal shipment management. The logistics segment provides truck brokerage, warehousing and distribution, international freight forwarding, and supply-chain management services. For more information on Pacer International visit www.pacer.com.

USE OF NON-GAAP FINANCIAL MEASURES: This press release contains “non-GAAP financial measures” as defined by the Securities and Exchange Commission. These non-GAAP measures are (1) adjusted intermodal revenues, adjusted intermodal gross margin and adjusted intermodal operating income, each of which excludes from annual 2011 results the impact of the previously announced volume reduction of the ocean carrier customer that transitioned its western business directly to the railroad and (2) adjusted income from operations and adjusted earnings per share for the fourth quarters of 2011 and 2012, each of which excludes the impact of realignment expense. Adjusted intermodal operating income also excludes the impact of the gain on sale of railcar assets which occurred in the third quarter of 2011. Non-GAAP measures are used by management and the Board of Directors in their analysis of the company’s ongoing core operating performance. Management believes that the non-GAAP financial measures provide useful supplemental information that is essential to a proper understanding of the operating results of the company’s core businesses and allows investors to more easily compare operating results from period to period. A tabular reconciliation of the differences between the non-GAAP financial information discussed in this release and the most directly comparable financial information calculated and presented in accordance with GAAP is contained in the financial summary statements attached to this press release.

CERTAIN FORWARD-LOOKING STATEMENTS—This press release contains or may contain forward-looking statements, including earnings per share guidance for fiscal year 2013, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on the company’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions. Among the important factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements are general economic and business conditions including the current U.S. and global economic environment and the timing and strength of economic recovery in the U.S. and internationally; industry trends, including changes in the costs of services from rail, motor, ocean and air transportation providers; and other risks discussed in the company’s Form 10-K and other filings with the Securities and Exchange Commission, which are incorporated herein by reference. Should one or more of these risks or uncertainties materialize, or should underlying assumptions or estimates prove incorrect, actual results may vary materially from those described herein as anticipated, believed, expected or intended. Except as otherwise required by federal securities laws, the company does not undertake any obligation to update such forward-looking statements whether as a result of new information, future events or otherwise.

Pacer International, Inc.

Unaudited Condensed Consolidated Balance Sheets

(in millions)

December 31, 2012 December 31, 2011
Assets
Current assets
Cash and cash equivalents $ 20.2 $ 24.0
Accounts receivable, net 132.7 133.5
Prepaid expenses and other 9.4 12.3
Deferred income taxes 2.4 4.0
Total current assets 164.7 173.8
Property and equipment
Property and equipment, cost 108.8 99.8
Accumulated depreciation (62.0 ) (56.1 )
Property and equipment, net 46.8 43.7
Other assets
Deferred income taxes 12.6 14.1
Other assets 9.9 11.7
Total other assets 22.5 25.8
Total assets $ 234.0 $ 243.3
Liabilities & Equity
Current liabilities
Accounts payable and other accrued liabilities $ 112.5 $ 127.1
Long-term liabilities
Other 1.3 0.9
Total liabilities 113.8 128.0
Stockholders’ equity
Common stock 0.4 0.4
Additional paid-in capital 305.7 304.7
Accumulated deficit (185.9 ) (190.2 )
Accumulated other comprehensive income 0.4
Total stockholders’ equity 120.2 115.3
Total liabilities and stockholders’ equity $ 234.0 $ 243.3
Pacer International, Inc.

Unaudited Condensed Consolidated Statements of Operations

(in millions, except share and per share data)

Three Months Ended Year Ended
December 31, 2012 December 31, 2011 December 31, 2012 December 31, 2011
Revenues $ 351.9 $ 358.0 $ 1,415.0 $ 1,478.5
Operating expenses:
Cost of purchased transportation and services 290.8 296.6 1,181.5 1,218.7
Direct operating expenses 25.2 25.7 101.6 105.8
Selling, general and administrative expenses 32.0 31.5 123.4 131.8
Other income (0.2 ) (0.4 ) (4.8 )
Total operating expenses 347.8 353.8 1,406.1 1,451.5
Income from operations 4.1 4.2 8.9 27.0
Interest expense (0.3 ) (0.5 ) (1.4 ) (2.3 )
Income before income taxes 3.8 3.7 7.5 24.7
Income tax expense (1.6 ) (2.6 ) (3.2 ) (10.8 )
Net income $ 2.2 $ 1.1 $ 4.3 $ 13.9
Earnings per share:
Basic:
Earnings per share $ 0.06 $ 0.03 $ 0.12 $ 0.40
Weighted average shares outstanding 35,085,571 34,978,646 35,069,099 34,959,819
Diluted:
Earnings per share $ 0.06 $ 0.03 $ 0.12 $ 0.40
Weighted average shares outstanding 35,406,118 35,194,541 35,338,338 35,066,417
Pacer International, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in millions)

Year Ended
December 31, 2012 December 31, 2011
Cash flows from operating activities
Net income $ 4.3 $ 13.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 7.9 7.2
Gain on sale of property and equipment (0.1 )
Gain on sale of railcar assets (4.7 )
Amortization of deferred gain on sale lease-back transactions (0.8 ) (0.7 )
Deferred taxes 2.5 12.4
Stock based compensation expense 1.8 2.4
Change in operating assets and liabilities
Accounts receivable, net 0.8 19.0
Prepaid expenses and other 2.9 3.1
Accounts payable and other accrued liabilities (14.4 ) (20.7 )
Other assets 2.0 1.8
Other liabilities (0.9 ) (0.2 )
Net cash provided by operating activities 6.1 33.4
Cash flows used in investing activities
Capital expenditures (11.4 ) (8.0 )
Purchase of railcar assets (28.4 ) (22.1 )
Net proceeds from sale of railcar assets 28.9
Net proceeds from sale lease-back transaction 30.2
Proceeds from sales of property and equipment 0.1 1.1
Net cash used in investing activities (9.5 ) (0.1 )
Cash flows used in financing activities
Net repayments under revolving line of credit agreement (13.4 )
Debt issuance costs paid to third parties (0.2 )
Repurchase and retirement of Pacer common stock (0.1 ) (0.1 )
Withholding tax paid upon vesting of restricted and performance stock units (0.1 )
Net cash used in financing activities (0.4 ) (13.5 )
Net increase (decrease) in cash and cash equivalents (3.8 ) 19.8
Cash and cash equivalents at beginning of year 24.0 4.2
Cash and cash equivalents at end of year $ 20.2 $ 24.0
Pacer International, Inc.

Unaudited Results by Segment

(in millions)

Three Months Ended December 31, Year Ended December 31,
2012 2011 Change % Change 2012 2011 Change % Change
Revenues
Intermodal $ 296.9 $ 289.7 $ 7.2 2.5 % $ 1,179.6 $ 1,175.3 $ 4.3 0.4 %
Logistics 57.3 68.3 (11.0 ) (16.1 ) 238.3 303.5 (65.2 ) (21.5 )
Inter-segment eliminations (2.3 ) (2.3 ) N/M (2.9 ) (0.3 ) (2.6 ) N/M
Total 351.9 358.0 (6.1 ) (1.7 ) 1,415.0 1,478.5 (63.5 ) (4.3 )
Cost of purchased transportation and services and direct operating expense 1/
Intermodal 268.1 263.6 4.5 1.7 1,077.2 1,062.5 14.7 1.4
Logistics 50.2 58.7 (8.5 ) (14.5 ) 208.8 262.3 (53.5 ) (20.4 )
Inter-segment eliminations (2.3 ) (2.3 ) N/M (2.9 ) (0.3 ) (2.6 ) N/M
Total 316.0 322.3 (6.3 ) (2.0 ) 1,283.1 1,324.5 (41.4 ) (3.1 )
Gross margin
Intermodal 28.8 26.1 2.7 10.3 102.4 112.8 (10.4 ) (9.2 )
Logistics 7.1 9.6 (2.5 ) (26.0 ) 29.5 41.2 (11.7 ) (28.4 )
Total $ 35.9 $ 35.7 $ 0.2 0.6 $ 131.9 $ 154.0 $ (22.1 ) (14.4 )
Gross margin percentage
Intermodal 9.7 % 9.0 % 0.7 % 8.7 % 9.6 % (0.9 )%
Logistics 12.4 14.1 (1.7 ) 12.4 13.6 (1.2 )
Total 10.2 % 10.0 % 0.2 % 9.3 % 10.4 % (1.1 )%
Income from operations
Intermodal $ 12.1 $ 9.8 $ 2.3 23.5 $ 38.4 $ 48.6 $ (10.2 ) (21.0 )
Logistics (2.4 ) (1.0 ) (1.4 ) (140.0 ) (10.4 ) (2.2 ) (8.2 ) (372.7 )
Corporate (5.6 ) (4.6 ) (1.0 ) (21.7 ) (19.1 ) (19.4 ) 0.3 1.5
Total $ 4.1 $ 4.2 $ (0.1 ) (2.4 )% $ 8.9 $ 27.0 $ (18.1 ) (67.0 )%
1/ Direct operating expenses are only incurred in the intermodal segment
Pacer International, Inc.

Reconciliation of Intermodal GAAP Results to Intermodal Adjusted Results

For the Years Ended December 31, 2012 and December 31, 2011

(in millions)

Year Ended
December 31, 2012
Year Ended December 31, 2011 AdjustedVariance

2012 vs 2011

% AdjustedVariance

2012 vs 2011

GAAPResults GAAPResults Adjustments AdjustedResults
Intermodal
Revenues $ 1,179.6 $ 1,175.3 $ (76.5 ) 1/ $ 1,098.8 $ 80.8 7.4 %
Gross margin 102.4 112.8 (7.3 ) 1/ 105.5 (3.1 ) (2.9 )%
Income from operations $ 38.4 $ 48.6 $ (12.0 ) 2/ $ 36.6 $ 1.8 4.9 %
1/ Adjustment to reflect impact of the previously announced reduction in volume from ocean carrier customer that transitioned its western U.S. intermodal business directly to the railroad. Purchased transportation and direct operating expenses were adjusted to the average intermodal margin percentage for the 2011 period.
2/ Adjustment to reflect impact of the previously announced reduction in volume from ocean carrier customer that transitioned its western U.S. intermodal business directly to the railroad. Purchased transportation and direct operating expenses were adjusted to the average intermodal margin percentage for the 2011 period. Also includes an adjustment to eliminate the gain on sale of railcar assets of $4.7 million which occurred in the third quarter of 2011.
Reconciliation of GAAP Results to Adjusted Results

For the Three Months Ended December 31, 2012 and 2011

(in millions, except per share data)

Three Months Ended December 31, 2012 Three Months Ended December 31, 2011
GAAPResults Adjustments AdjustedResults GAAPResults Adjustments AdjustedResults
Income from operations – Total $ 4.1 $ 0.8 1/ $ 4.9 $ 4.2 $ 0.3 3/ $ 4.5
Earnings per share – Basic 0.06 0.02 2/ 0.08 0.03 0.04 4/ 0.07
Earnings per share – Diluted $ 0.06 $ 0.02 2/ $ 0.08 $ 0.03 $ 0.04 4/ $ 0.07
1/ Adjustment reflects the elimination of realignment expense for 2012.
2/ Adjustment reflects the elimination of realignment expense for 2012, net of tax
3/ Adjustment reflects the elimination of realignment expense for 2011.
4/ Adjustment reflects the elimination of realignment expense for 2011, net of tax and the elimination of the deferred tax asset adjustment during the fourth quarter of 2011.
Reclassifications of 2011 Results to Conform to 2012 Presentation

For the Three Months and the Year Ended December 31, 2011

(in millions)

Three Months Ended December 31, 2011
As Originally
Reported
Reclassification
Amount 1/
As Reclassified
Cost of purchased transportation and services $ 293.9 $ 2.7 $ 296.6
Direct operating expenses 23.1 2.6 25.7
Selling, general and administrative expenses 35.0 (3.5 ) 31.5
Depreciation and amortization $ 1.8 $ (1.8 ) $
Year Ended December 31, 2011
As Originally
Reported
Reclassification
Amount 1/
As Reclassified
Cost of purchased transportation and services $ 1,208.4 $ 10.3 $ 1,218.7
Direct operating expenses 94.7 11.1 105.8
Selling, general and administrative expenses 146.0 (14.2 ) 131.8
Depreciation and amortization $ 7.2 $ (7.2 ) $
Three Months Ended December 31, 2011
As Originally
Reported
Reclassification
Amount 1/
As Reclassified
Gross margin
Intermodal $ 28.7 $ (2.6 ) $ 26.1
Logistics 12.3 (2.7 ) 9.6
Total $ 41.0 $ (5.3 ) $ 35.7
Gross margin percentage
Intermodal 9.9 % 9.0 %
Logistics 18.0 14.1
Total 11.5 % 10.0 %
Year Ended December 31, 2011
As Originally
Reported
Reclassification
Amount 1/
As Reclassified
Gross margin
Intermodal $ 123.9 $ (11.1 ) $ 112.8
Logistics 51.5 (10.3 ) 41.2
Total $ 175.4 $ (21.4 ) $ 154.0
Gross margin percentage
Intermodal 10.5 % 9.6 %
Logistics 17.0 13.6
Total 11.9 % 10.4 %
1/ Certain reclassifications have been made to the 2011 operating expenses in order to conform to the 2012 presentation. The reclassifications had no impact on previously reported income. Specifically, Pacer reclassified certain expenses from selling, general and administrative to costs of purchased transportation and services and direct operating expenses. Pacer also reclassified depreciation and amortization as direct operating expenses, and selling, general and administrative expenses.
Reclassifications of 2011 and 2012 Quarterly Results to Conform to 2012 Presentation

(in millions)

Three Months Ended
March 31,
2011
June 30,
2011
September 30,

2011

December 31,
2011
March 31,
2012
June 30,2012 September 30,

2012

December 31,
2012
RECLASSIFIED AMOUNTS 1/
Intermodal
Cost of purchased transportation and services $ $ $ $ $ $ $ $
Direct operating expenses 2.8 2.7 3.0 2.6 2.7 2.8 2.7 2.7
Selling, general and administrative expenses (1.7 ) (1.4 ) (1.8 ) (1.4 ) (1.5 ) (1.5 ) (1.2 ) (1.2 )
Depreciation and amortization (1.1 ) (1.3 ) (1.2 ) (1.2 ) (1.2 ) (1.3 ) (1.5 ) (1.5 )
Logistics
Cost of purchased transportation and services 2.5 2.5 2.6 2.7 3.2 3.4 3.5 3.7
Direct operating expenses
Selling, general and administrative expenses (2.0 ) (2.1 ) (2.1 ) (2.2 ) (2.8 ) (3.0 ) (3.1 ) (3.3 )
Depreciation and amortization $ (0.5 ) $ (0.4 ) $ (0.5 ) $ (0.5 ) $ (0.4 ) $ (0.4 ) $ (0.4 ) $ (0.4 )
AS RECLASSIFIED 1/
Intermodal
Cost of purchased transportation and services $ 226.8 $ 246.1 $ 245.9 $ 237.9 $ 235.8 $ 256.5 $ 240.4 $ 242.9
Direct operating expenses 26.8 27.2 26.1 25.7 25.0 25.4 26.0 25.2
Selling, general and administrative expenses 17.5 17.4 17.8 16.3 15.9 15.5 15.9 16.7
Depreciation and amortization
Gross Margin $ 25.9 $ 30.6 $ 30.2 $ 26.1 $ 24.1 $ 24.9 $ 24.6 $ 28.8
Gross Margin Percentage 9.3 % 10.1 % 10.0 % 9.0 % 8.5 % 8.1 % 8.5 % 9.7 %
Logistics
Cost of purchased transportation and services $ 68.1 $ 72.0 $ 63.5 $ 58.7 $ 53.3 $ 54.3 $ 51.0 $ 50.2
Direct operating expenses
Selling, general and administrative expenses 11.1 10.7 11.0 10.6 11.0 10.0 9.4 9.7
Depreciation and amortization
Gross Margin $ 10.9 $ 10.5 $ 10.2 $ 9.6 $ 7.8 $ 7.5 $ 7.1 $ 7.1
Gross Margin Percentage 13.8 % 12.7 % 13.8 % 14.1 % 12.8 % 12.1 % 12.2 % 12.4 %
Consolidated
Cost of purchased transportation and services $ 294.8 $ 318.0 $ 309.3 $ 296.6 $ 289.0 $ 310.5 $ 291.2 $ 290.8
Direct operating expenses 26.8 27.2 26.1 25.7 25.0 25.4 26.0 25.2
Selling, general and administrative expenses 32.9 33.6 33.8 31.5 31.9 29.9 29.6 32.0
Depreciation and amortization
Gross Margin $ 36.8 $ 41.1 $ 40.4 $ 35.7 $ 31.9 $ 32.4 $ 31.7 $ 35.9
Gross Margin Percentage 10.3 % 10.6 % 10.8 % 10.0 % 9.2 % 8.8 % 9.1 % 10.2 %
1/ Certain reclassifications have been made to the 2011 and 2012 quarterly operating expenses in order to conform to the 2012 presentation. The reclassifications had no impact on previously reported income. Specifically, Pacer reclassified certain expenses from selling, general and administrative to costs of purchased transportation and services and direct operating expenses. Pacer also reclassified depreciation and amortization as direct operating expenses, and selling, general and administrative expenses.
Thursday, February 7th, 2013 Uncategorized Comments Off on Pacer International (PACR) Reports Fourth Quarter Results

Lantronix (LTRX) xPrintServer Wins MacObserver Editors Choice Award Again

IRVINE, CA — (Marketwire) — 02/07/13 — Lantronix, Inc. (NASDAQ: LTRX), a leading global provider of smart M2M connectivity solutions, today announced that the Lantronix xPrintServer™ – Office Edition won the Editors Choice Award from MacObserver during Macworld | iWorld 2013. The xPrintServer – Office Edition is designed specifically for office use by business and IT professionals wishing to print from their iPad®, iPhone® or iPod® Touch to virtually any printer. Last year, the Lantronix xPrintServer – Network Edition was honored with an Editors Choice Award from MacObserver during Macworld | iWorld 2012.

“From ease-of-use to active directory, to the USB port and enhanced security and accounting features, the xPrintServer Office Edition makes printing throughout the enterprise a snap,” said Mark D. Tullio, vice president of worldwide marketing for Lantronix. “The xPrintServer represents Lantronix’s continuing commitment to delivering high quality, innovative, secure and easy-to-deploy solutions. We could not be more pleased to have the newest edition to the xPrintServer family recognized among so many innovative products at Macworld.”

The xPrintServer: Open it. Plug it in. Print!
The xPrintServer family is an easy-to-use hardware solution that utilizes the iOS native print menu. As the industry’s first and only plug-and-print hardware solution for printing from iPads, iPhones and virtually any iOS device, the xPrintServer is also offered in a Home Edition, which is intended for the consumer. With automatic printer discovery and no configuration, printing is hassle-free. Simply open the box, plug in power and Ethernet, and print — from any iOS device running iOS version 4.2 or later, to virtually any USB or network-connected printer, whether wired or wireless.

Additional Links:
xPrintServer micro site – http://www.xPrintServer.com

xPrintServer – Office Edition launch video: http://www.lantronix.com/xprintserver-office-video/

xPrintServer – Home Edition launch video: http://www.lantronix.com/xprintserver-home-video/

Demo (installation) video: http://www.lantronix.com/xprintserver-demo-video/

How to Buy
The xPrintServer – Office Edition retails for $199.95 MSRP, while the xPrintServer – Home Edition retails for $99.95 MSRP. Both editions are also available from Lantronix.com, as well as a variety of e-tailers including Amazon, Best Buy Online, Buy.com, CDW, DataVision, Ebyte.com, Insight Enterprises, MacMall, Mavtechonline.com, NeutronUSA, Newegg.com, NextDayPC.com, NextWarehouse.com, PCMall, PowerMax.com, Provantage, SemiconductorStore.com, SoftwareForLess, and more.

The xPrintServer currently supports thousands of networked printer models from leading printer families including HP, Brother, Epson, Canon, Dell, Lexmark, and Xerox. As new printer brands and printer models become available, Lantronix will post updates on www.Lantronix.com.

About Lantronix
Lantronix, Inc. (NASDAQ: LTRX) is a global leader of secure M2M (machine-to-machine) communication technologies that simplify access and communication with and between virtually any electronic device. Our smart connectivity solutions enable sharing data between devices and applications to empower businesses to make better decisions based on real-time information, and gain a competitive advantage by generating new revenue streams, improving productivity and increasing efficiency and profitability. Easy to integrate and deploy, Lantronix products remotely and securely connect electronic equipment via networks and the Internet. Founded in 1989, Lantronix serves some of the largest medical, security, industrial and building automation, transportation, retail/POS, financial, government, consumer electronics/appliances, IT/data center and pro-AV/signage entities in the world. The company’s headquarters are located in Irvine, Calif.

For more information, visit www.lantronix.com. The Lantronix blog, http://www.lantronix.com/blog, features industry discussion and updates. Follow Lantronix on Twitter at http://www.twitter.com/Lantronix.

© 2013 Lantronix, Inc. Lantronix, Inc. and Lantronix are registered trademarks, and xPrintServer is a trademark of Lantronix, Inc. iPad, iPhone, iPod, iPod classic, iPod nano, and iPod touch are trademarks of Apple, Inc., registered in the U.S. and other countries. All other trademarks and trade names are the property of their respective holders. Specifications subject to change without notice. All rights reserved.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Contact:
Stephanie Olsen
Lages & Associates, Inc.
stephanie@lages.com
949.453.8080

Investor Contact:
E.E. Wang
Wang Strategic Communications
investors@lantronix.com
310-877-6039

Company Contact:
Mark D. Tullio
Lantronix
mark.tullio@lantronix.com

Thursday, February 7th, 2013 Uncategorized Comments Off on Lantronix (LTRX) xPrintServer Wins MacObserver Editors Choice Award Again

Take Back the Kingdom in Glu Mobile’s (GLUU) Dragon Storm

Take Back the Kingdom in Glu Mobile’s Dragon Storm
New MMO freemium game challenges players with real-time, strategic gameplay

San Francisco, Calif. – Feb. 7, 2013 – Glu Mobile Inc. (NASDAQ: GLUU), a leading global developer and publisher of freemium games for smartphone and tablet devices, today announced the availability of Dragon Storm, the company’s new MMO freemium game. Dragon Storm is a strategic, fantasy combat game that challenges players to take back control of a fully 3D world overrun by the evil dragon-god, Shadowclaw. As players build their kingdoms and progress through the game’s solo campaigns, they will have the multiplayer option to fight with others around the globe, either as solo mortal lords or as members of kingdom alliances. Dragon Storm’s live chat and player-to-player messaging functions offer a true MMO experience.

“Dragon Storm presents fans of MMO gaming an imaginative dragon world with strategic gameplay and a sophisticated alliance dynamic,” said Mike DeLaet, SVP of Global Publishing. “Players will enjoy Dragon Storm’s emphasis on player-vs.-player gameplay as they fight to build up their kingdom and climb the leaderboards.”

In Dragon Storm, players must strengthen their kingdoms by amassing resources and raising armies of soldiers and dragons. In addition to completing Dragon Storm’s solo campaigns, players may also become part of an alliance – either by joining an existing alliance or creating their own. Alliance members have the ability to strategize in real-time through the games chat and player-to-player messaging functionality. Player alliances will battle to gain strength, resources, and position on the in-game leaderboards.

Features of Dragon Storm include:

  • Build Your Kingdom – Amass vast armies of fantasy soldiers and dragon creatures.
  • Fight Back Against Shadowclaw – Take back the kingdom by completing hundreds of quests and solo story campaigns.
  • Join a Global Alliance – Battle with other Dragon Lords from all over the world and strategize in real-time.
  • Battle Rivals – Compete with other alliances for domination of the leaderboards.
  • Play Across Multiple Devices – Utilize iCloud for cross-device play.

Dragon Storm is available for free from the App Store http://bit.ly/11XSdkz.

###

Glu Mobile
Glu Mobile (NASDAQ:GLUU) is a leading global developer and publisher of freemium games for smartphone and tablet devices. Glu is focused on creating compelling original IP games such as CONTRACT KILLER, GUN BROS, DEER HUNTER, BLOOD & GLORY, and SAMURAI VS. ZOMBIES DEFENSE on a wide range of platforms including iOS, Android, Windows Phone, Google Chrome, and MAC OS. Glu’s unique technology platform enables its titles to be accessible to a broad audience of consumers globally. Founded in 2001, Glu is headquartered in San Francisco with a major office outside Seattle, and international locations in Canada, China, and Russia. Consumers can find high-quality entertainment wherever they see the ‘g’ character logo or at www.glu.com. For live updates, please follow Glu via Twitter at www.twitter.com/glumobile or become a Glu fan at Facebook.com/glumobile.

DRAGON STORM, CONTRACT KILLER, GUN BROS, DEER HUNTER, BLOOD & GLORY, SAMURAI VS. ZOMBIES DEFENSE, GLU, GLU MOBILE and the ‘g’ character logo are trademarks of Glu Mobile Inc.

Media Contacts
Jason Enriquez
Glu Mobile Inc.
PR@glu.com
(415) 800-6263

Thursday, February 7th, 2013 Uncategorized Comments Off on Take Back the Kingdom in Glu Mobile’s (GLUU) Dragon Storm

India Globalization Capital (IGC) Announces the Extension of Warrants’ Expiry Date

Bethesda, Maryland, Feb. 7, 2013 (GLOBE NEWSWIRE) — India Globalization Capital, Inc. (NYSE MKT: IGC), a company competing in the rapidly growing materials and infrastructure industry in India and China, today announced the extension of the expiration date for 11,855,122 outstanding warrants listed on the NYSE MKT exchange with ticker symbol  IGC.WT and CUSIP number (45408X118).

The warrants have an exercise price of $5.00 and were scheduled to expire on March 8, 2013. The expiration date of the warrants has been extended from 5:00 p.m. New York time on March 8, 2013 until 5:00 p.m. New York time on Friday, March 6, 2015.  As was the case prior to the extension, the warrants are subject to earlier expiration if the Company exercises its right to call the warrants for redemption. All other terms remain the same.

The Company has filed a registration statement with the Securities and Exchange Commission to register the shares underlining the warrants to permit the exercise of the warrants.  Currently, the Company has such a registration statement effective.  Holders of the warrants will be able to exercise the warrants for cash since such a registration statement is effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the shares underlying the warrants in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Currently IGC has three securities listed: Common Stock (IGC), Warrants (IGC.WT) and the Units (IGC.U).   As previously disclosed the Company intends to delist the Units and continue listing the other two securities.  Investors holding the Units are encouraged to contact the Company in order to split the Units into common stock and warrants.  None of a) the delisting of the Units, 2) splitting of the Units, or 3) extension of the Warrant expiration will have any bearing on the basic or fully diluted shares outstanding.

About IGC:

Based in Bethesda, Maryland, India Globalization Capital, Inc. (IGC) is a materials and infrastructure company operating in India and China.  We currently supply Iron ore to Steel Companies operating in China.  For more information about IGC, please visit IGC’s Web site at www.indiaglobalcap.com. For information about Ironman, please visit www.hfironman.net.

Forward-looking Statements:

Some of the statements contained in this press release that are not historical facts constitute forward-looking statements under the federal securities laws.  Forward-looking statements can be identified by the use of the words “may,” “will,” “should,” “could,” “expects,” “post”, “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “intends,” “potential,” “proposed,” “confident” or “continue” or the negative of those terms.  These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond IGC’s control and are difficult to predict.  Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, our competitive environment, infrastructure demands, Iron ore availability and governmental, regulatory, political, economic, legal and social conditions in China and India.

The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.  Other factors and risks that could cause or contribute to actual results differing materially from such forward-looking statements have been discussed in greater detail in IGC’s Schedule 14A, Form 10-K for FYE 2012, Form 10-Q for the quarter ended September 30, 2012, Form S-3, and the Post-effective Amendment No. 1 on Form S-3 to Form S-1 filed with the Securities and Exchange Commission on December 9, 2011, July 16, 2012, November 14, 2012, December 14, 2012, and December 26, 2012 respectively.

CONTACT: Investors Contact Information
         Claudia Grimaldi
         301-983-0998

IGC

Thursday, February 7th, 2013 Uncategorized Comments Off on India Globalization Capital (IGC) Announces the Extension of Warrants’ Expiry Date

Sutor (SUTR) Reports Second Quarter Fiscal 2013

71.4% Increase in Second Quarter Net Income on 46.3% Increase in Revenues

CHANGSHU, China, Feb. 7, 2013 /PRNewswire-FirstCall/ — Sutor Technology Group Limited (the “Company” or “Sutor”) (Nasdaq: SUTR), a leading China-based manufacturer and distributor of high-end fine finished steel products and welded steel pipes used by a variety of downstream applications, today announced its financial results for fiscal 2013 second quarter ended December 31, 2012.

Second quarter fiscal 2013 results highlights:

2Q FY2013

2Q FY2012

Change

Revenue (million)

$157.9

$107.9

46.3%

Gross profit (million)

$12.2

$10.4

17.3%

Net income (million)

$4.8

$2.8

71.4%

EPS (fully diluted)

$0.12

$0.07

71.4%

Discussing second quarter fiscal 2013 results, Lifang Chen, Chairwoman and CEO of Sutor, commented, “We are pleased to report that we substantially improved our top and bottom lines, expanded our product offering, introduced new products and services, and further diversified our customer base.”

Second Quarter FY2013 vs. Second Quarter FY2012 Highlights

  • The 46.3% increase in revenue was mainly due to an 87.0% increase in sales volume, partially offset by a 21.7% decrease in the average selling price (ASP) primarily due to lower costs of raw materials. As the Chinese economy continues to gradually regain its strength, we anticipate stable or higher steel product prices in the coming quarters.
  • Revenue generated from domestic sales increased by 49.2% to $139.6 million, while revenue generated from international sales increased by 27.5% to $18.3 million. As a percentage of total revenue, international sales accounted for 11.6%, as compared to 13.3% in the same quarter of fiscal 2012.
  • Our gross margin decreased due to changes in the product mix, as we sold more acid pickled steel products which have lower gross margin as compared to other products.
  • Total operating expenses (selling expenses and general and administrative expenses) slightly decreased despite higher revenue, mainly due to cost control measures.
  • Higher revenue, lower operating expenses, lower interest expenses and higher interest income contributed to a 71.4% increase in net income.

Liquidity

  • Operating activities provided approximately $6.2 million of cash in the six months ended December 31, 2012. As of December 31, 2012, cash and cash equivalents (excluding restricted cash) were $17.8 million and restricted cash were $99.4 million.
  • Sutor’s major sources of liquidity are borrowings through short-term bank loans. As of December 31, 2012, short-term loans totaled approximately $112.9 million, and the current portion of long-term loans was $30.8 million. The Company also had approximately $3.4 million long-term loans.
  • As of December 31, 2012, Sutor had an unused line of credit with banks of approximately $34.7 million which entitles the Company to draw bank loans for general corporate purposes.  Sutor expects sufficient liquidity to carry out normal operations for fiscal 2013.

Recent Business Developments

  • The new high precision cold-rolled steel production line with a designed annual capacity of 500,000 metric tons (MT) is expected to start trial operations in the first half of calendar year 2013. Once operational, we expect this new line will increase our cold-rolled steel capacity to 750,000 MT. Cold-rolled steel products are used as raw materials to manufacture hot-dip galvanized and pre-painted galvanized steel products, for which we have a capacity of 700,000 MT and 200,000 MT, respectively.
  • We are making progress on our recently established electronic commerce B2B platform, a complementary business to our existing capital intensive and asset heavy steel processing business. We believe that this platform has significant upside potential. We are currently using it to promote and sell our own products to existing customers. Additionally, we plan to introduce this platform to other companies in the heavy industry to promote and sell their products.
  • We recently started commercial production of galvolume steel plates. Derived from hot-dip aluminum galvanization and hot-dip zinc galvanization technology, our galvolume steel plates possess exceptional anti-corrosion, anti-oxidation and electric-chemical properties, which make it less prone to rust and corrosion. As a result, this product can be used in a variety of industries such as construction, household appliances, automobiles, machinery and shipping.

Ms. Chen concluded, “We have well positioned our Company to take advantage of additional opportunities arising from China’s expected economic recovery. Sutor’s business is strong and competitive, and should continue to profitably grow in fiscal 2013.”

Conference Call Information

Sutor’s management will host an earnings conference call today, February 7, 2013, at 9:00 a.m. U.S. Eastern time/10:00 pm Beijing/Hong Kong time. Listeners may access the call by dialing US: +1877 847 0047, CN: 800 876 5011, HK +852 3006 8101, access code: SUTR. A recording of the call will be available shortly after the call through March 9, 2013. Listeners may access it by dialing US: +1866 572 7808, CN: 800 876 5013, HK: +852 3012 8000, access code: 689245.

Functional Currency

The reporting currency of the Company is the United States Dollar (“USD”). Sutor and Sutor BVI maintain their books and records in USD, their functional currency. The PRC subsidiaries maintain their books and records in its local currency, the Renminbi Yuan (“RMB”), which is their functional currency as being the primary currency of the economic environment in which these entities operate. In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not USD are translated into USD, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiaries are recorded as a separate component of accumulated other comprehensive income.

About Sutor Technology Group Limited

Sutor is one of the leading China-based manufacturers and distributors of high-end fine finished steel products and welded steel pipes used by a variety of downstream applications. The Company utilizes a variety of in-house developed processes and technologies to convert steel manufactured by third parties into fine finished steel products, including hot-dip galvanized steel, pre-painted galvanized steel, acid-pickled steel, cold-rolled steel and welded steel pipe products. To learn more about the Company, please visit http://www.sutorcn.com/en/index.php.

Forward-Looking Statements

This press release includes certain statements that are not descriptions of historical facts, but are forward-looking statements.  Such statements include, among others, those concerning our expected financial performance, liquidity and strategic and operational plans, our future operating results, our expectations regarding the market for our products, our expectations regarding the steel market, as well as all assumptions, expectations, predictions, intentions or beliefs about future events.  You are cautioned that any such forward-looking statements are not guarantees of future performance and that a number of risks and uncertainties could cause our actual results to differ materially from those anticipated, expressed or implied in the forward-looking statements.  These risks and uncertainties include, but not limited to, the factors mentioned in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended June 30, 2012, and other risks mentioned in our other reports filed with the Securities Exchange Commission (“SEC”).  Copies of filings made with the SEC are available through the SEC’s electronic data gathering analysis retrieval system (EDGAR) at http://www.sec.gov.  The words “believe,” “expect,” “anticipate,” “project,” “targets,” “optimistic,” “intend,” “aim,” “will” or similar expressions are intended to identify forward-looking statements.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  The Company assumes no obligation and does not intend to update any forward-looking statements, except as required by law.

For more information, please contact:

China

US

Jason Wang, Director of IR

Lena Cati, IR Representative

Sutor Technology Group Limited

The Equity Group

Tel: +86-512-5268-0988

Tel: 212 836-9611

Email: investor_relations@sutorcn.com

Email: lcati@equityny.com

Financial Tables Below:

SUTOR TECHNOLOGY GROUP LIMITED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

December 31,

June 30,

2012

2012

ASSETS

Current Assets:

Cash and cash equivalents

$

17,798,409

$

9,530,531

Restricted cash

99,395,193

111,582,149

Short-term investments

4,849,112

Trade accounts receivable, net of allowance for doubtful accounts of $566,912 and $1,306,099

as of December 31, 2012 and June 30, 2012, respectively

3,860,126

7,023,880

Notes receivable

110,960

475,112

Other receivables and prepayments, net of allowance for doubtful accounts of $335,588 and

$351,372 as of December 31, 2012 and June 30, 2012, respectively

3,427,375

4,275,817

Advances to suppliers, unrelated parties, net of allowance for doubtful accounts of $414,811 and

$366,697 as of December 31, 2012 and June 30, 2012, respectively

33,393,020

27,446,626

Advances to suppliers, related parties, net of right to offset (Note 10)

137,031,287

121,884,833

Inventories, net

57,809,111

50,432,279

Deferred tax assets

889,819

709,688

Total Current Assets

353,715,300

338,210,027

Non-current Assets:

Advances for purchase of long term assets

15,349,526

15,001,088

Property, plant and equipment, net

74,589,227

77,231,273

Intangible assets, net

6,565,187

3,082,877

Investments in affiliated company

6,356,497

Total Non-current Assets

102,860,437

95,315,238

TOTAL ASSETS

$

456,575,737

$

433,525,265

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:

Short-term loans

$

112,884,062

$

111,166,838

Long-term loans, current portion

30,786,516

27,762,975

Accounts payable, unrelated parties

51,315,445

57,079,617

Accounts payable, related parties

17,976,698

Other payables and accrued expenses

7,747,798

8,820,064

Advances from customers

13,300,180

7,924,812

Warrant liabilities

32,881

47,404

Total Current Liabilities

234,043,580

212,801,710

Long-Term Loans

3,437,544

8,490,772

Total Liabilities

237,481,124

221,292,482

Stockholders’ Equity

Undesignated preferred stock – $0.001 par value; 1,000,000 shares authorized; nil shares

outstanding

Common stock – $0.001 par value;

authorized: 500,000,000 shares as of December 31, 2012 and June 30, 2012;

issued: 40,855,602 and 40,805,602 shares as of December 31, 2012 and June 30, 2012.

40,855

40,805

Additional paid-in capital

41,415,780

41,344,306

Statutory reserves

18,100,361

18,100,361

Retained earnings

124,340,415

117,732,738

Accumulated other comprehensive income

35,848,711

35,622,241

Less: Treasury stock, at cost, 590,838 and 544,477 shares as of December 31, 2012 and June 30,

2012, respectively

(651,509)

(607,668)

Total Stockholders’ Equity

219,094,613

212,232,783

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

456,575,737

$

433,525,265

SUTOR TECHNOLOGY GROUP LIMITED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME

For The Three Months Ended

For The Six Months Ended

December 31,

December 31,

2012

2011

2012

2011

Revenue:

Revenue from unrelated parties

$

106,478,486

$

83,070,982

$

195,593,572

$

181,467,497

Revenue from related parties

51,388,372

24,823,816

79,459,977

56,622,918

157,866,858

107,894,798

275,053,549

238,090,415

Cost of Revenue

Cost of revenue from unrelated parties

(96,462,341)

(74,930,923)

(178,489,766)

(165,952,519)

Cost of revenue from related parties

(49,195,171)

(22,552,581)

(75,807,453)

(50,737,745)

(145,657,512)

(97,483,504)

(254,297,219)

(216,690,264)

Gross Profit

12,209,346

10,411,294

20,756,330

21,400,151

Operating Expenses:

Selling expenses

(1,978,916)

(2,078,492)

(4,292,168)

(4,414,272)

General and administrative expenses

(2,550,249)

(2,578,617)

(4,680,073)

(5,504,115)

Total Operating Expenses

(4,529,165)

(4,657,109)

(8,972,241)

(9,918,387)

Income from Operations

7,680,181

5,754,185

11,784,089

11,481,764

Other Incomes/(Expenses):

Interest income

1,059,709

388,207

2,022,050

678,415

Interest expense

(2,340,244)

(2,438,976)

(5,874,436)

(4,167,516)

Changes in fair value of warrant liabilities

(1,501)

22,082

14,523

232,466

Equity in gains of affiliated company

185,888

174,446

Other income

122,520

14,592

159,138

19,950

Other expense

(563,209)

(477,176)

(667,524)

(858,667)

Total Other Expenses, net

(1,536,837)

(2,491,271)

(4,171,803)

(4,095,352)

Income Before Taxes

6,143,344

3,262,914

7,612,286

7,386,412

Income tax (expense)/benefit

(1,371,012)

(460,504)

(1,004,609)

400,329

Net Income

$

4,772,332

$

2,802,410

$

6,607,677

$

7,786,741

Other Comprehensive Income:

Foreign currency translation adjustment

708,871

1,375,046

226,470

3,862,447

Comprehensive Income

$

5,481,203

$

4,177,456

$

6,834,147

$

11,649,188

Basic Earnings per Share

$

0.12

$

0.07

$

0.16

$

0.19

Diluted Earnings per Share

$

0.12

$

0.07

$

0.16

$

0.19

Basic Weighted Average Shares Outstanding

40,224,003

40,487,224

40,222,247

40,602,179

Diluted Weighted Average Shares Outstanding

40,224,003

40,487,224

40,222,247

40,602,179

SUTOR TECHNOLOGY GROUP LIMITED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For The Six Months Ended

December 31,

2012

2011

Cash Flows from Operating Activities:

Net income

$

6,607,677

$

7,786,741

Adjustments to reconcile net income to net cash provided by/(used in) operating activities

Depreciation and amortization

4,408,037

4,179,300

Reversal for doubtful accounts

(708,630)

Stock based compensation

71,524

61,257

Foreign currency exchange gain

(10,234)

(686,395)

Loss on disposal of property, plant and equipment

85,198

Interest income from short-term investments carried at amortized cost

(30,900)

Equity in gains of affiliated company

(174,446)

Deferred income taxes

(179,476)

(47,431)

Changes in fair value of warrant liabilities

(14,523)

(232,466)

Changes in current assets and liabilities:

Restricted cash for notes payable

2,221,324

(50,625,460)

Trade accounts receivable

3,910,051

(7,624,315)

Notes receivable

364,553

(526,505)

Other receivable and prepayments

868,254

269,075

Advances to suppliers, unrelated parties

(5,968,905)

6,087,748

Advances to suppliers, related parties

(15,026,467)

1,984,400

Inventories

(7,330,679)

(46,491,155)

Accounts payable, unrelated parties

(5,156,443)

60,932,832

Accounts payable, related parties

17,975,273

Other payables and accrued expenses

(1,078,382)

222,530

Other payables, related parties

(601,014)

Advances from customers

5,368,031

(5,520,486)

Net Cash Provided by/(Used In) Operating Activities

6,200,837

(30,831,344)

Cash Flows from Investing Activities:

Purchase of property, plant and equipment, net of value added tax refunds received

(3,217,771)

(9,786,882)

Proceeds from disposal of property, plant and equipment

523,761

Purchase of intangible assets

(3,560,563)

Investment in affiliated company

(6,181,547)

Proceeds from sale of short-term investments

4,884,009

Net Cash Used In Investing Activities

(7,552,111)

(9,786,882)

Cash Flows from Financing Activities:

Proceeds from loans

94,118,588

128,876,501

Repayment of loans

(94,530,050)

(102,275,514)

Restricted cash for bank loans

10,065,475

Payments on repurchase of common stock

(43,841)

(534,269)

Net Cash Provided by Financing Activities

9,610,172

26,066,718

Effect of Exchange Rate Changes on Cash and Cash Equivalents

8,980

228,347

Net Change in Cash and Cash Equivalents

8,267,878

(14,323,161)

Cash and Cash Equivalents at Beginning of Period

9,530,531

21,324,931

Cash and Cash Equivalents at End of Period

$

17,798,409

$

7,001,770

Supplemental Non-Cash Information:

Offset of notes payable to related parties against receivable from related parties

$

10,609,363

$

10,263,357

Supplemental Cash Flow Information:

Cash paid during the period for interest expense

$

(5,025,598)

$

(3,915,785)

Cash (paid)/received during the period for income tax

$

(1,669,952)

$

6,019

Thursday, February 7th, 2013 Uncategorized Comments Off on Sutor (SUTR) Reports Second Quarter Fiscal 2013

VistaGen’s (VSTA) Collaborators Identify Definitive Precursor for Adult Blood and the Immune System

http://www.vistagen.com/wp-content/themes/vistagen/images/logo.gif

SOUTH SAN FRANCISCO, CA — (Marketwire) — 02/07/13 — VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced significant advancements in its stem cell technology licensed from the University Health Network (UHN) in Toronto, Canada. The advancements, which improve VistaGen’s ability to develop new stem cell-based bioassay systems and potentially improved cell therapies for human blood system disorders, were reported in the December 2012 edition of Cell Reports, an open-access journal from Cell Press.

The exclusively licensed stem cell technology from UHN, which applies equally to both embryonic stem cells and induced pluripotent stem cells (iPS cells), enables the efficient production of mature hematopoietic (blood) precursor cells. These blood cell precursors give rise to red cells, granulocytes and immune cells (lymphocytes), which represent the majority of the blood cells found in the body.

“In collaboration with our long-term strategic partners at UHN, we continue to pioneer stem cell technology that promises to change the way we develop medicine and apply treatment,” stated Shawn K. Singh, CEO of VistaGen. “In addition to creating new capabilities and in vitro assays for drug rescue and predictive toxicology, these advancements open the door to development of new treatments for bone marrow failure, anemia, viral diseases and other conditions that compromise the immune system.”

“Due to only partial understanding of the timing and control of the development of definitive hematopoiesis in humans, scientists were previously limited in their ability to identify and produce, from human pluripotent stem cells, the important precursor for mature red and white cells of the blood,” said H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer. “The identification and characterization of this important precursor provides a readily accessible pluripotent stem cell-derived target cell population that can be expanded and matured into the types of cells needed for novel in vitro assays and our drug rescue efforts, and enables improved technologies and approaches for future cell therapy collaborations.”

Dr. Gordon Keller, Chairman of UHN’s McEwen Centre for Regenerative Medicine in Toronto and co-founder of VistaGen, stated, “We’ve been working for many years studying in vitro differentiation of pluripotent stem cells trying to identify, and then expand, the first human cell capable of producing the adult blood and immune system. I believe that we now have a better understanding of this important transition from embryonic to adult hematopoiesis, and have the tools to develop improved methods to expand this cell in large numbers for both drug development and cell therapy applications.”

About VistaGen Therapeutics
VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen’s drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

VistaGen’s small molecule prodrug candidate, AV-101, has completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen’s stem cell technology-based drug rescue, predictive toxicology and metabolism screening activities, further development of stem cell-based bioassay systems, and potentially improved cell therapies, for human blood system disorders or other diseases or conditions, clinical development and commercialization of AV-101 for neuropathic pain or any other disease or condition, its ability to enter into strategic predictive toxicology, metabolism screening, drug rescue and/or drug discovery, development and commercialization collaborations and/or licensing arrangements with respect to one or more drug rescue variants, cell therapies or AV-101, risks and uncertainties relating to the availability of substantial additional capital to support its research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to any drug rescue variant or cell therapy identified and developed by VistaGen, or AV-101. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For more information:
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
Atlanta, Georgia
www.MissionIR.com
404-941-8975

Thursday, February 7th, 2013 Uncategorized Comments Off on VistaGen’s (VSTA) Collaborators Identify Definitive Precursor for Adult Blood and the Immune System

China Armco (CNAM) Updates Recycling Business on New Qualification and Orders

SAN MATEO, Calif., Feb. 6, 2013 /PRNewswire/ — China Armco Metals, Inc. (NYSE MKT: CNAM) (“China Armco” or the “Company”), a distributor of imported metal ore and metal recycler with a new state-of-the-art scrap metal recycling facility in China, today announced that Armco (Lianyungang) Renewable Metals, Inc. (“Armco Lianyungang”), the Company’s wholly owned subsidiary, has been certified as a Demonstration Base for Steel Scrap Processing and Distribution by the China Steel Scrap Industrial Associations, and therefore could benefit from a 50% value added tax (VAT) refund in 2013 according to the upcoming policy of the Chinese government.

Armco Lianyungang was selected among steel scrap companies in China upon assessment in respect of scale, equipment conditions, quality and environmental management systems and credit rating etc., pursuant to regulations promulgated by the Ministry of Industry and Information Technology of China in October 2012.

In addition, the Company has so far received orders amounted to approximately 360,000 metric tons of scrap steel for the year of 2013, which accounts for 60% of the Company’s annual sales goal for 2013.

“We are confident that we will benefit from the certification as well as the possible tax refund. The tax refund when effective could lower our costs and increase our profits by a large margin, which may ease our capital stress and improve our competitive edge. Also, with the certification we are allowed to act as procurement agency for other uncertified companies, which could boost our domestic purchases and total sales,” said Mr. Kexuan Yao, Chairman and CEO of China Armco.  “In addition, we had a very good start for 2013 compared to previous years. So far the orders we have received for 2013 are significantly more than the same period of previous years. We believe that we will have a significant increase in sales in 2013.”

ABOUT CHINA ARMCO METALS, INC.
China Armco is engaged in the sale and distribution of metal ore and non-ferrous metals and the recycling business in China. China Armco’s customers include some of the fastest growing steel producing mills and foundries throughout China. Raw materials are acquired from a group of global suppliers located in various countries, including, but not limited to, Brazil, India, Indonesia, Ukraine and the United States. China Armco has product lines of ferrous and non-ferrous ore, iron ore, chrome ore, nickel ore, magnesium, copper ore, manganese ore, steel billet and recycled scrap metals. For more information about China Armco, please visit http://www.armcometals.com.

SAFE HARBOR STATEMENT
In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, China Armco, is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations regarding our revenues and production related to our scrap metal recycling operations, pricing and demand for our product lines and the extent of government imposed energy and monetary policy restrictions and resulting blackouts and associated impact on our trading and recycling operations.

We caution that actual results could differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. This press release is qualified in its entirety by the following, including, but not limited to, any expectations with respect to the Company’s revenues and operations, institution of governmental regulations relating to our businesses and the international economic climate, and the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2011, and our Quarterly Filings on Form 10-Q for the periods ended March 31, 2012, June 30, 2012 and September 30, 2012, respectively.

CONTACT INFORMATION:

China Armco Metals, Inc.
US Contact
Christina Xiong
Office: 650.212.7620
Email: christina@armcometals.com
ir@armcometals.com
Website: www.armcometals.com

China Contact:
Ripple Zhang
Office: 86-21-62375286
Email: ripple.zhang@armcometals.com
Website: www.armcometals.com

Wednesday, February 6th, 2013 Uncategorized Comments Off on China Armco (CNAM) Updates Recycling Business on New Qualification and Orders

NuPathe (PATH) to Present at the Leerink Swann 2013 Global Healthcare Conference

CONSHOHOCKEN, PA — (Marketwire) — 02/06/13 — NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Armando Anido, chief executive officer, will present a company overview at the Leerink Swann 2013 Global Healthcare Conference on Wednesday, February 13, 2013, at 2:30 p.m. EST. The conference is being held at the Waldorf Astoria in New York, NY.

A live audio webcast of the presentation will be available via the “Investor Relations” page of the NuPathe website, www.nupathe.com. Please log on through NuPathe’s website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on NuPathe’s website for 90 days following the presentation.

About NuPathe
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe’s lead product candidate, Zecuity™ (sumatriptan iontophoretic transdermal system) has been approved by the FDA for the acute treatment of migraine with or without aura in adults. Zecuity is expected to be available by prescription in the fourth quarter of 2013. In addition to Zecuity, NuPathe has two proprietary product candidates based on its LAD™, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson’s disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for Zecuity and its other product candidates in the U.S. and territories throughout the world.

For more information about NuPathe, please visit our website and our blog at www.nupathe.com. You can also follow us on StockTwits (stocktwits.nupathe.com), Twitter (twitter.nupathe.com), SlideShare (slideshare.nupathe.com) and LinkedIn (linkedin.nupathe.com).

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: the potential benefits of, and commercial opportunity for, Zecuity and NuPathe’s other product candidates; partnering plans for Zecuity and NuPathe’s other product candidates; the timing of the expected launch and availability of Zecuity; and other statements relating to NuPathe’s plans, objectives, expectations and beliefs regarding its future operations, performance, financial condition and other future events. Forward-looking statements are based upon management’s current expectations and beliefs and are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and events to differ materially from those indicated herein including, among others: NuPathe’s ability to obtain sufficient capital to launch Zecuity; NuPathe’s ability to obtain commercial and development partners for Zecuity and its other product candidates; NuPathe’s reliance on third parties to manufacture Zecuity; NuPathe’s ability to establish and effectively manage its supply chain; NuPathe’s ability to establish effective marketing and sales capabilities; market acceptance among physicians and patients and the availability of adequate reimbursement from third party payors for Zecuity; and the risks, uncertainties and other factors discussed in NuPathe’s Annual Report on Form 10-K for the year ended December 31, 2010 and Quarterly Report on Form on Form 10-Q for the quarter ended September 30, 2012 under the caption “Risk Factors” and elsewhere in such reports, which are available on NuPathe’s website at www.nupathe.com in the “Investor Relations — SEC Filings” section. While NuPathe may update certain forward-looking statements from time to time, it specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise. You are cautioned not to place undue reliance on any forward-looking statements.

Contact Information:

Investor Contacts
John Woolford
Westwicke Partners, LLC
(443) 213-0506
john.woolford@westwicke.com

Keith A. Goldan
Vice President & Chief Financial Officer
NuPathe Inc.

Wednesday, February 6th, 2013 Uncategorized Comments Off on NuPathe (PATH) to Present at the Leerink Swann 2013 Global Healthcare Conference

China HGS (HGSH) Reports First Quarter of Fiscal Year 2013 Results

HANZHONG, China, Feb. 6, 2013 /PRNewswire-FirstCall/ — China HGS Real Estate Inc. (NASDAQ: HGSH) (“China HGS” or the “Company”), a leading regional real estate developer headquartered in Hanzhong City, Shaanxi Province, China, today reported its financial results for the first quarter of fiscal 2013 ended December 31, 2012.

Highlights for the First Quarter of Fiscal 2013

  • Total revenues for the first quarter of fiscal 2013 were $11.0 million, an increase of 339.8% from $2.5 million in the first quarter of fiscal 2012
  • Total gross floor area (“GFA”) sold during the first quarter of fiscal 2013 was 13,028 square meters, more than tripled from 3,877.4 square meters sold in the first quarter of fiscal 2012
  • Net income totaled $5.5 million, a significant increase compared to the net income of $1.0 million in the first quarter of fiscal 2012
  • Basic and diluted net earnings per share (“EPS”) attributable to shareholders were $0.12, compared to $0.02 for the first quarter of fiscal 2012

“We are pleased to report strong financial results for the first quarter of fiscal 2013. We achieved significantly higher revenues and net income than the same quarter of last year, demonstrating our improved operational performance and higher returns on invested capital,” commented Mr. Xiaojun Zhu, China HGS’s Chairman and Chief Executive Officer. “Despite the purchase and mortgage restriction policies imposed on real estate market remained in effect, we experienced higher sales activities in the quarter driven by our sales and promotion efforts. These results are very encouraging. We believe the fundamentals underpinning real estate demand in Tier 3 and Tier 4 cities and counties remain strong as the population continues to grow in these cities and counties driven by increased urbanization.”

“We now look ahead to 2013 with expectations for somewhat relaxed government policies on the real estate industry and some rebound in the Chinese housing market,” continued Mr. Zhu. “Given these expectations, we have been focusing on the investment in three large projects – Mingzhu Beiyuan, Oriental Pearl Garden, and Yangzhou Pearl Garden. We expect to complete the construction of these three multi-building large apartment complexes in two to three years. We have already started pre-sales and signed some sales contracts with buyers. We expect these three large projects to provide us significant revenue and income growth in 2014 and beyond,” concluded Mr. Xiaojun Zhu.

Financial Results for the First Quarter of Fiscal 2013

Revenues increased by 339.8% to approximately $11.0 million for the first quarter of fiscal 2013 from approximately $2.5 million for the same period in the last year. The total GFA sold during the quarter was 13,028 square meters, representing over three times increase from 3,877 square meters sold in the same quarter of last year. A significant portion of revenue during the first quarter of fiscal 2013 was from the sales of our commercial units inventory in NanDajie Project (Mingzhu Xinju project) with a total GFA of 4,545.88 square meters for a total contract amount of approximately $5.4 million.

Gross profit was approximately $6.5 million for the first quarter of fiscal 2013 as compared to approximately $1.4 million for the first quarter of fiscal 2012, representing an increase of $5.1 million. The higher gross profit was mainly attributable to the increase in sales. The overall gross profit as a percentage of revenue increased to 58.7% during the first quarter of fiscal 2013 from 57.7% for the same quarter of last year, mainly due to higher sales of commercial units, which have higher average selling price per square meter compared to that of residential properties.

Total operating expenses increased to $722,065 for the first quarter of fiscal 2013 from $361,213 for the first quarter of fiscal 2012 as a result of more sales and marketing activities, increased sales commission, higher executive compensation, taxes, and office expenses. However, as a percentage of total sales, operating expenses declined to 6.6% from 14.4% in the same quarter of last year, demonstrating an improved operating efficiency achieved in this quarter,

The Company reported net income of approximately $5.5 million for the first quarter of fiscal 2013, as compared to net income of $1.0 million for the first quarter of fiscal 2012, representing an increase of $4.5 million. The higher net income was primarily due to the increase in revenue.

As of December 31, 2012, the Company had total cash and restricted cash balance of approximately $1.7 million, decreased by $0.5 million compared to $2.2 million cash and restricted cash balance as of September 30, 2012.

Safe Harbor Statement

This press release contains forward-looking statements, which are subject to change. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All “forward-looking statements” relating to the business of China HGS Real Estate Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties which could cause actual results to differ. These factors include but are not limited to: the uncertain market for the Company’s business, macroeconomic, technological, regulatory, or other factors affecting the profitability of real estate business; and other risks related to the Company’s business and risks related to operating in China. Please refer to the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2012, as well as the Company’s Quarterly Reports on Form 10-Q that have been filed since the date of such annual report, for specific details on risk factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The Company’s actual results could differ materially from those contained in the forward-looking statements. The Company undertakes no obligation to revise or update its forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

About China HGS Real Estate, Inc.

China HGS Real Estate, Inc. (NASDAQ: HGSH), founded in 1995 and headquartered in Hanzhong City, Shaanxi Province, is a leading real estate developer in the region and holds the national grade I real estate qualification. The Company focuses on the development of high-rise, sub-high-rise residential buildings and multi-building apartment complexes in China’s Tier 3 and Tier 4 cities and counties with rapidly growing populations driven by increased urbanization. The Company provides affordable housing with popular and modern designs to meet the needs of multiple buyer groups. The Company’s development activity spans a range of services, including land acquisition, project planning, design management, construction management, sales and marketing, and property management. For further information about China HGS, please go to www.chinahgs.com.

CHINA HGS REAL ESTATE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

December 31,

September 30,

2012

2012

ASSETS

Current assets:

Cash

$

523,868

$

1,104,686

Restricted cash

1,161,158

1,080,985

Accounts receivable

4,654,636

Advances to vendors

4,376,112

2,566,422

Loans to outside parties, net

5,146

20,957

Real estate property development completed

15,912,612

19,534,088

Real estate property under development

9,582,760

8,590,275

Other current assets

181,873

171,863

Total current assets

36,398,165

33,069,276

Property, plant and equipment, net

1,017,668

1,037,080

Real estate property development completed, net of current portion

6,565,509

6,691,813

Security deposits for land use right

22,959,737

22,894,698

Real estate property under development, net of current portion

61,575,793

56,021,787

Total Assets

$

128,516,872

$

119,714,654

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

4,145,774

$

3,828,880

Other payables

1,395,244

1,213,394

Construction deposits

301,773

301,318

Customer deposits

13,875,722

11,597,422

Shareholder loan

1,810,000

1,810,000

Accrued expenses

2,402,089

2,305,086

Taxes payable

3,722,182

4,336,458

Total current liabilities

27,652,784

25,392,558

Construction deposits, net of current portion

866,385

864,259

Customer deposits, net of current portion

18,562,385

17,743,993

Total liabilities

47,081,554

44,000,810

Commitments and Contingencies

Stockholders’ equity

Common stock, $0.001 par value, 100,000,000 shares

authorized, 45,050,000 shares issued and outstanding

December 31, 2012 and September 30, 2012

$

45,050

$

45,050

Additional paid-in capital

17,753,749

17,750,337

Statutory surplus

6,549,354

6,549,354

Retained earnings

50,403,306

44,894,229

Accumulated other comprehensive income

6,683,859

6,474,874

Total stockholders’ equity

81,435,318

75,713,844

Total Liabilities and Stockholders’ Equity

$

128,516,872

$

119,714,654

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CHINA HGS REAL ESTATE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME  AND COMPREHENSIVE INCOME

(Unaudited)

Three months ended December 31,

2012

2011

Real estate sales

$

11,003,415

$

2,501,981

Less: Sales tax

(710,717)

(175,905)

Cost of real estate sales

(3,830,244)

(881,900)

Gross profit

6,462,454

1,444,176

Operating expenses

Selling and distribution expenses

161,094

42,441

General and administrative expenses

560,971

318,772

Total operating expenses

722,065

361,213

Operating income

5,740,389

1,082,963

Interest expense

(18,100)

(4,163)

Other income – net

7,952

Income  before income taxes

5,730,241

1,078,800

Provision for income taxes

221,164

48,338

Net income

5,509,077

1,030,462

Other comprehensive income

Foreign currency translation adjustment

208,985

$

344,589

Comprehensive income

$

5,718,062

$

1,375,051

Basic and diluted income per common share

Basic

$

0.12

$

0.02

Diluted

$

0.12

$

0.02

Weighted average common shares outstanding

Basic

45,050,000

45,050,000

Diluted

45,050,000

45,050,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CHINA HGS REAL ESTATE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three months ended December 31,

2012

2011

Cash flows from operating activities

Net income

$

5,509,077

$

1,030,462

Adjustments to reconcile net income to net used in operating activities:

Depreciation

22,404

22,081

Stock based compensation

3,412

12,175

Changes in assets and liabilities:

Restricted cash

(77,263)

(5,750)

Accounts receivable

(4,664,334)

Advances to vendors

(1,806,155)

51,748

Loans to outside parties

15,903

579,495

Security deposits for land use rights

(9,136,065)

Real estate property development completed

3,830,244

881,900

Real estate property under development

(6,376,199)

(1,898,986)

Other current assets

(9,542)

(15,367)

Accounts payables

306,655

(3,203,189)

Other payables

178,775

310,247

Customer deposits

3,019,617

3,021,626

Construction deposits

(731)

6,272

Accrued expenses

90,860

(122,461)

Taxes payable

(627,900)

(32,172)

Net cash used in operating activities

$

(585,177)

$

(8,497,984)

Cash flow from financing activities

Proceeds from shareholder loan

3,142,332

Repayment of shareholder loan

(3,142,332)

Net cash provided by financing activities

$

$

Effect of changes of foreign exchange rate on cash

4,359

25,795

Net decrease in cash

(580,818)

(8,472,189)

Cash, beginning of period

1,104,686

8,837,795

Cash, end of period

$

523,868

$

365,606

Supplemental disclosures of cash flow information:

Interest paid

$

$

Income taxes paid

$

404,003

$

18,817

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Wednesday, February 6th, 2013 Uncategorized Comments Off on China HGS (HGSH) Reports First Quarter of Fiscal Year 2013 Results

Harris Interactive® (HPOL) Reports Second Quarter Fiscal 2013 Results

ROCHESTER, N.Y., Feb. 6, 2013 /PRNewswire/ — Harris Interactive Inc. (NASDAQ: HPOL), a leading global market research firm, today announced its second quarter fiscal 2013 financial results.

Al Angrisani, President and Chief Executive Officer of Harris Interactive, commented, “Today’s announcement of improved earnings guidance over last year’s earnings is a strong indication that the turnaround is progressing on schedule. Our improved profitability has allowed us to continue to de-leverage our balance sheet and position ourselves to pay off all remaining bank debt by fiscal year end. As our turnaround continues, the major task that remains is to continue to strengthen the sales engine of the Company by focusing our sales efforts on our core product strengths as well as some of our new product offerings.”

Key Financial Statistics (1)

USD in millions – unaudited

For the Three Months
Ended December 31,

For the Six Months
Ended December 31,

2012

2011

2012

2011

Revenue (2)

$     37.1

$     39.1

$   70.1

$    76.9

Operating income (loss) (3)

$       3.0

$       2.3

$     4.8

$    (2.0)

Net income (loss)

$       2.9

$       1.6

$     4.6

$    (4.3)

Fully diluted net income (loss) per share

$     0.05

$     0.03

$   0.08

$  (0.08)

Adjusted EBITDA (4)

$       4.8

$      4.0

$     8.3

$      1.6

Adjusted EBITDA with add-back of restructuring and other charges (4)

$       4.8

$      4.0

$     8.3

$      6.9

Cash provided by operations

$       1.6

$      3.3

$     1.9

$      3.5

Bookings (5)

$     47.8

$    45.2

$   81.7

$    77.3

At December 31:

2012

2011

Cash and cash equivalents

$      11.1

$    14.1

Outstanding debt

$        3.6

$      8.4

Secured revenue (6)

$      54.1

$    45.1

________

(1)

All amounts shown reflect our Asian operations as discontinued operations.

(2)

Amounts include the impact of foreign currency exchange rate differences. Excluding the impact of foreign currency exchange rate differences, revenue for the three and six months ended December 31, 2012 decreased by 5% and 8%, respectively, over the same prior year periods.

(3)

Operating income for the three and six months ended December 31, 2012 did not include any restructuring or other charges, compared with $(0.1) million and $5.4 million, respectively,  for the same prior year periods.

(4)

EBITDA is a non-GAAP measure. Adjusted EBITDA, also a non-GAAP measure, is EBITDA with stock-based compensation added back.

(5)

Amounts include the impact of foreign currency exchange rate differences. Excluding the impact of foreign currency exchange rate differences, bookings for the three and six months ended December 31, 2012 increased by 5% for both current periods, over the same prior year periods.

(6)

Amounts include the impact of foreign currency exchange rate differences. Excluding the impact of foreign currency exchange rate differences, secured revenue at December 31, 2012 increased by 19% over the same prior year period.

Full Year Fiscal 2013 Guidance

Eric Narowski, Chief Financial Officer of Harris Interactive, commented, “Based on current market conditions and forecasts, the Company projects Adjusted EBITDA to be between $13.5 and $14.5 million for the fiscal year ending June 30, 2013.”

Second Quarter Fiscal 2013 Results Conference Call and Webcast Access

Al Angrisani, President and Chief Executive Officer, will host a conference call to discuss these results on Wednesday, February 6, 2013, at 5:00 p.m. ET. Formal remarks will be followed by a question and answer session.

To access the conference call, please dial toll-free 877.303.9858 in the United States and Canada, or 408.337.0139 internationally.

A live webcast of the conference call also will be accessible via the Investor Relations section of our website at http://ir.harrisinteractive.com/, where an archived replay of the webcast will be available for 30 days following the call. No telephone replay of the conference call will be provided. This media release will be available under the Investor Relations section of our website at http://ir.harrisinteractive.com/ prior to the call.

Cautionary Note Regarding Forward Looking Statements

Certain statements in this press release and oral statements made by the Company on its conference call constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, among others, statements as to future economic performance, projections as to financial items, estimates, and plans and objectives for future operations, products and services. In some cases, you can identify forward-looking statements by terminology such as, “may”, “should”, “expects”, “plans”, “anticipates”, “feel”, “believes”, “estimates”, “predicts”, “potential”, “continue”, “consider”, “possibility”, or the negative of these terms or other comparable terminology. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, without limitation, risks detailed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K, as updated quarterly in our Quarterly Reports on Form 10-Q to reflect additional material risks. The Company has filed its reports on Forms 10-K and 10-Q with the Securities and Exchange Commission, and they are available under the Investor Relations section of our website at http://ir.harrisinteractive.com/. Risks and uncertainties also include the continued volatility of the global macroeconomic environment and its impact on the Company and its clients, the Company’s ability to sustain and grow its revenue base, the Company’s ability to maintain and improve cost efficient operations, the impact of reorganization, restructuring and related charges, quarterly variations in financial results, the Company’s ability to maintain compliance with certain NASDAQ listing requirements, actions of competitors, the Company’s ability to develop and maintain products and services attractive to the market, and the Company’s ability to remain in compliance with the financial covenants in its credit agreement.

You are urged to consider these factors carefully in evaluating such forward-looking statements and are cautioned not to place undue reliance on them. The forward-looking statements are qualified in their entirety by this cautionary statement.

About Harris Interactive

Harris Interactive is one of the world’s leading market research firms, leveraging research, technology, and business acumen to transform relevant insight into actionable foresight. Known widely for the Harris Poll® and for pioneering innovative research methodologies, Harris offers proprietary solutions in the areas of market and customer insight, corporate brand and reputation strategy, and marketing, advertising, public relations and communications research. Harris possesses expertise in a wide range of industries including health care, technology, public affairs, energy, telecommunications, financial services, insurance, media, retail, restaurant, and consumer package goods. Additionally, Harris has a portfolio of multi-client offerings that complement our custom solutions while maximizing our client’s research investment. Serving clients in more than 196 countries and territories through our North American and European offices, Harris specializes in delivering research solutions that help us – and our clients-stay ahead of what’s next. For more information, please visit www.harrisinteractive.com.

HPOL – E

HARRIS INTERACTIVE INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

December 31,

June 30,

2012

2012

Assets

Cash and cash equivalents

$         11,085

$    11,456

Accounts receivable, net

27,234

19,940

Unbilled receivables

6,512

7,513

Prepaids and other current assets

3,663

3,859

Deferred tax assets

156

243

Total current assets

48,650

43,011

Property, plant and equipment, net

2,335

2,500

Other intangibles, net

9,551

10,795

Other assets

1,131

1,080

Total assets

$         61,667

$    57,386

Liabilities and Stockholders’ Equity

Accounts payable

$          9,122

$      7,628

Accrued expenses

17,343

21,643

Current portion of long-term debt

3,596

4,794

Deferred revenue

14,264

10,088

Liabilities from discontinued operations

181

Total current liabilities

44,325

44,334

Long-term debt

1,199

Deferred tax liabilities

1,497

1,696

Other long-term liabilities

3,165

4,072

Total stockholders’ equity

12,680

6,085

Total liabilities and stockholders’ equity

$         61,667

$    57,386

HARRIS INTERACTIVE INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

(Unaudited)

Three Months Ended

Six Months Ended

December 31,

December 31,

2012

2011

2012

2011

Revenue from services

$       37,087

$       39,115

$       70,097

$       76,884

Operating expenses:

Cost of services

21,898

24,380

41,353

48,010

Selling, general and administrative

11,207

11,308

21,985

22,973

Depreciation and amortization

963

1,197

1,911

2,490

Restructuring and other charges

(72)

5,368

Total operating expenses

34,068

36,813

65,249

78,841

Operating income (loss)

3,019

2,302

4,848

(1,957)

Operating margin

8.1%

5.9%

6.9%

-2.5%

Interest expense, net

69

204

170

361

Income (loss) from continuing operations before
income taxes

2,950

2,098

4,678

(2,318)

Provision for income taxes

58

283

43

3

Income (loss) from continuing operations

2,892

1,815

4,635

(2,321)

Loss from discontinued operations

(190)

(2,011)

Net income (loss)

$         2,892

$         1,625

$         4,635

$        (4,332)

Basic net income (loss) per share:

Continuing operations

$           0.05

$           0.03

$           0.08

$          (0.04)

Discontinued operations

(0.00)

(0.04)

Basic net income (loss) per share

$           0.05

$           0.03

$           0.08

$          (0.08)

Diluted net income (loss) per share:

Continuing operations

$           0.05

$           0.03

$           0.08

$          (0.04)

Discontinued operations

(0.00)

(0.04)

Diluted net income (loss) per share

$           0.05

$           0.03

$           0.08

$          (0.08)

Weighted average shares outstanding:

Basic

56,152,326

55,272,335

56,171,401

55,149,610

Diluted

57,412,623

55,294,426

57,395,320

55,149,610

Harris Interactive Inc.

Three and Six Months Ended December 31, 2012

Reconciliation of GAAP Net Income (Loss) to EBITDA and Adjusted EBITDA

Amounts in thousands of USD

Three Months Ended

Six Months Ended

December 31,

December 31,

2012

2011

2012

2011

GAAP net income (loss)

$      2,892

$     1,625

$   4,635

$  (4,332)

Loss from discontinued operations

190

2,011

Interest expense, net

69

204

170

361

Provision for income taxes

58

283

43

3

Depreciation and amortization

1,127

1,462

2,243

2,980

EBITDA

$      4,146

$     3,764

$   7,091

$   1,023

Stock-based compensation (7)

679

271

1,248

550

Adjusted EBITDA

$      4,825

$     4,035

$   8,339

$   1,573

Adjusted EBITDA

$      4,825

$     4,035

$   8,339

$   1,573

Add-back of restructuring and other charges

(72)

5,368

Adjusted EBITDA with add-back of restructuring and other charges

$      4,825

$     3,963

$   8,339

$   6,941

(7) Stock-based compensation expense represents the cost of stock-based compensation
accounted for under the FASB guidance for stock-based compensation.

Full Year Fiscal 2013 Guidance

Reconciliation of GAAP Net Income (Loss) to EBITDA and Adjusted EBITDA

Amounts in millions of USD

For the Fiscal Year Ending June 30, 2013 (1)(2)

For the Fiscal Year Ended June 30, 2012

GAAP net income (loss)

$                    7.0

$              (5.6)

Loss from discontinued operations, net of tax

1.9

Interest expense, net

0.2

0.7

Provision for income taxes

0.1

0.2

Depreciation and amortization

4.4

5.6

EBITDA

$                  11.7

$               2.8

Stock-based compensation (3)

2.3

1.8

Adjusted EBITDA

$                  14.0

$               4.6

Adjusted EBITDA

$                  14.0

$               4.6

Add-back of restructuring and other charges

7.5

Adjusted EBITDA with add-back of restructuring and other charges

$                  14.0

$             12.1

(1) This reconciliation is based on the midpoint of the Adjusted EBITDA guidance range provided in this press release.

(2) The amounts expressed in this column are based on current estimates as of the date of this press release.

(3) Stock-based compensation expense represents the cost of stock-based compensation accounted for under the
FASB guidance for stock-based compensation.

Press Contact:
Michael T. Burns
Investor Relations
Harris Interactive Inc.
800-866-7655 x7328
mburns@harrisinteractive.com

SOURCE Harris Interactive

Wednesday, February 6th, 2013 Uncategorized Comments Off on Harris Interactive® (HPOL) Reports Second Quarter Fiscal 2013 Results

Cache, Inc. (CACH) Reports Inducement Grant under NASDAQ Rule 5635(c)(4)

As previously announced, on February 5, 2013, Jay Margolis joined Cache, Inc. (NASDAQ: CACH) as Chairman of the Board of Directors and Chief Executive Officer. In connection with his employment by Cache, Mr. Margolis was awarded stock options that qualify as an inducement grant pursuant to the NASDAQ Listing Rules. The NASDAQ Listing Rules require the distribution of a press release in connection with any inducement grant. This press release is intended to satisfy those requirements.

In connection with his employment by Cache, Mr. Margolis was granted an option to purchase 1,000,000 shares of Cache’s common stock. The option will vest in equal installments on the first, second and third anniversary of the grant date, subject to accelerated vesting upon a change of control or termination of employment without cause. Any unvested portion of the option will be forfeited upon a termination of employment by Mr. Margolis for any reason or due to death or disability. The vested and unvested portions of the option will be forfeited upon a termination of employment for cause. The exercise price of the option is $3.34 per share.

About Cache, Inc.

Cache is a nationwide, mall-based specialty retailer of sophisticated sportswear and social occasion dresses targeting style-conscious women who have a youthful attitude and are self-confident. The Company currently operates 261 stores, primarily situated in central locations in high traffic, upscale malls in 42 states, the Virgin Islands and Puerto Rico.

Wednesday, February 6th, 2013 Uncategorized Comments Off on Cache, Inc. (CACH) Reports Inducement Grant under NASDAQ Rule 5635(c)(4)

BIOLASE (BIOL) Receives FDA Clearance for Its 940nm Soft Tissue Laser

IRVINE, CA — (Marketwire) — 02/06/13 — BIOLASE, Inc. (NASDAQ: BIOL), the world’s leading manufacturer and distributor of dental lasers, announced today that the U.S. Food and Drug Administration (FDA) has cleared the 940nm Diolase 10 diode soft tissue laser for use in 19 additional medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery. This FDA clearance includes over 80 different procedures.

“We are very pleased to receive clearance for such a broad number of indications and procedures for the Diolase 10 diode soft tissue laser. Obtaining clearance for so many procedures across such a wide range of medical markets clearly demonstrates that our diode laser products are well suited for a vast array of surgical procedures,” said Federico Pignatelli, Chairman and Chief Executive Officer.

“Clearance for our Diolase 10 is the first step in enabling us to leverage our recently released, next-generation 940nm EPIC 10™ modular diode soft tissue dental laser platform and consumable business across a wide range of multi-billion dollar medical markets with appropriate strategic partners,” continued Pignatelli.

BIOLASE’s diode lasers are used in dentistry for surgical soft tissue procedures as an alternative to invasive and traumatic conventional devices, such as the high-speed drill, scalpel or electrosurge. The 940nm wavelength is better absorbed by hemoglobin (Hb) and oxyhemoglobin (HbO2) than other diode laser wavelengths(1), so it cuts efficiently at low power and with considerably less heat and discomfort, making it an excellent alternative to conventional surgical devices. BIOLASE’s 940nm wavelength is also FDA cleared for tooth whitening and temporary pain relief in a number of BIOLASE products.

“This is an exciting time at BIOLASE as we continue to expand the capabilities, applications, and indications for our core technologies so that they can be leveraged within our core dental market as well as into a number of other promising medical and veterinary markets,” said Fred Furry, Chief Operating Officer and Chief Financial Officer. “We will use the clearances received for the Diolase 10, now established as a 940nm diode laser predicate device, to obtain the same clearances for our EPIC 10 platform, which uses the same wavelength.”

“In conjunction with the Oculase MD, the 940nm diode laser is a surgical tool that every ophthalmology and oculoplastic practice should consider adding. It will allow the practitioner to offer more in-office surgery procedures to patients, rather than taking the time and expense incurred with the use of a surgery center,” said Daniel Durrie, M.D., internationally-recognized refractive surgeon and founder of Durrie Vision, a world-class refractive surgery center and research department located in the Kansas City area.

BIOLASE will be exhibiting its 940nm EPIC 10 diode soft-tissue laser for dental procedures, tooth whitening, and pain therapy, as well as its many other dental products, at several upcoming conferences including: the Western Veterinary Medical Conference from February 17-21 in Las Vegas, NV; the 148th Mid-Winter Meeting from February 21-23 in Chicago, Illinois; and the International Dental Show from March 12-16 in Cologne, Germany.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company’s laser products incorporate approximately 290 patented and patent-pending technologies designed to provide biological treatment and clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment and CAD/CAM systems. BIOLASE has sold more than 21,000 lasers.

Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

(1) Tunér, Jan & Hode, Lars. The New Laser Therapy Handbook. Fig 1.14, 41-42. Grängesberg, Sweden: Prima-Books, 2010. See graphical illustration in Attachment A.

Add to Digg Bookmark with del.icio.us Add to Newsvine

For further information, please contact:
Lisa Wilson
In-Site Communications, Inc.

Wednesday, February 6th, 2013 Uncategorized Comments Off on BIOLASE (BIOL) Receives FDA Clearance for Its 940nm Soft Tissue Laser

IsoRay (ISR) Metastatic Brain Cancer Video Released by Cornell Weill

Video To Be Used As A Training Tool For A New Multi-Institutional Study To Be Launched

RICHLAND, Wash., Feb. 5, 2013 /PRNewswire/ — IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation video by Cornell Weill demonstrating their techniques in the successful treatment of metastatic brain cancers using IsoRay’s patented Cesium-131 (Cs-131) sutured seeds.

Dr. Theodore H. Schwartz and Dr. Gabriella Wernicke, both of Weill Cornell Medical Center, presented their findings for the membership of The Society of Neuro-Oncology (SNO), titled “The study of Neurosurgical Resection and Intra-operative Cesium-131 Radio-isotope Brachytherapy in Patients with newly Diagnosed Brain Metastases,” available at  http://www.isoray.com/assets/Updated_SNO_Poster.pdf. In the study, which showed Cesium-131’s relative effectiveness in treating these tumors compared to other common treatments, the seeded sutures were placed within the resected tumor bed at the time of surgery to provide immediate radiation therapy to it and to a margin depth of 5 mm which is dosed to prevent tumor reoccurrence. The video which can be seen at http://www.youtube.com/watch?v=eor8gaXQKSE&feature=youtu.be demonstrates the single procedure method of delivering radiation just to the cancer tumor bed immediately following resection while providing the patient the opportunity for improved quality of life.

A metastatic, or secondary, brain tumor is one that begins as cancer in another part of the body. Some of the cancer cells may be carried to the brain by the blood or lymphatic fluid, or may spread from adjacent tissue. Metastatic brain tumors are often referred to as lesions or brain metastases. Metastatic brain tumors are the most common brain tumors.

IsoRay CEO Dwight Babcock says this multi institutional study will greatly advance the awareness to take on difficult cancers throughout the body utilizing the company’s Cesium-131 brachytherapy seeds and liquid isotopes.  “We are advancing our domestic and international goal of creating widespread awareness and adoption of Cesium-131 in hopes that these experiences will ultimately make it a standard of care.  The exceptional results that have been realized by Cornell in metastatic brain cancer have already garnered the interest of 5 major medical centers which have expressed interest I participating in the multi institutional study.  We believe Cesium-131’s ability to fight cancer and improve the quality of life for the men, women, and children who are battling these devastating cancers distinguishes it from other treatment options.”

IsoRay is the exclusive manufacturer of Cesium-131.  The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices.

About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body.  Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Contact:
Worldwide Financial
(954) 360-9998
info@wwfinancial.com

Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the advantages of our Cesium-131 seed, the advantages of Cesium-131 in mesh form, whether adoption of Cesium-131 will continue to increase, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether treatment of brain cancer using Cesium-131 will be successful in future cases, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA.  It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with Cesium-131 are favorable and in line with the conclusions of  clinical studies and initial patient results, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use Cesium-131 in its various forms, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.

Tuesday, February 5th, 2013 Uncategorized Comments Off on IsoRay (ISR) Metastatic Brain Cancer Video Released by Cornell Weill

Dover Saddlery (DOVR) Announces Preliminary Financial Results for Fourth Quarter 2012

LITTLETON, MA — (Marketwire) — 02/05/13 — Dover Saddlery, Inc. (NASDAQ: DOVR), the leading multichannel retailer of equestrian products, today announced that preliminary unaudited revenues for the fourth quarter ended December 31, 2012 exceeded revenues in the fourth quarter of 2011 by 11.0%, increasing to approximately $26.4 million. Revenues from the retail channel increased 16.7% to approximately $10.5 million and revenues from the direct channel increased 7.6% to approximately $15.9 million.

“We are very pleased that our new seasonal promotions in the fourth quarter of 2012 yielded such strong results, particularly in light of the challenging retail environment In addition, enhancements we made to our online channel throughout the year produced impressive results for the direct channel in the fourth quarter,” said Stephen L. Day, president and CEO of Dover Saddlery. “The sales numbers presented are preliminary, and we will be reporting the audited fourth quarter and full year 2012 results on or about March 26, 2013.”

About Dover Saddlery, Inc.
Dover Saddlery, Inc. (NASDAQ: DOVR) is the leading multichannel retailer of equestrian products in the United States. Founded in 1975 in Wellesley, Massachusetts, by United States Equestrian team members, Dover Saddlery has grown to become The Source® for equestrian products. Dover offers a broad and distinctive selection of competitively priced, brand-name products for horse and rider through catalogs, the Internet and company-owned retail stores. Dover Saddlery, Inc. serves the English rider and, through Smith Brothers, the Western rider. The Source®, Dover Saddlery® and Smith Brothers® are registered marks of Dover Saddlery.

For more information, please call 1-978-952-8062 or visit www.DoverSaddlery.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including without limitation statements made about the Company’s business outlook, the prospects for overall revenue growth, variations in consumer demand, gross margins and profitability, and the opening of new stores. All statements other than statements of historical fact included in this press release regarding the Company’s strategies, plans, objectives, expectations, and future operating results are forward-looking statements. Although Dover believes that the expectations reflected in such forward-looking statements are reasonable at this time, it can give no assurance that such expectations will prove to have been correct. These forward-looking statements involve significant risks and uncertainties, including those discussed in this release and others that can be found in “Item 1A Risk Factors” of Dover Saddler’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. Dover Saddlery is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Dover Saddlery projects.

Janet Nittmann
Email Contact
Tel 978 952 8062 x218

Tuesday, February 5th, 2013 Uncategorized Comments Off on Dover Saddlery (DOVR) Announces Preliminary Financial Results for Fourth Quarter 2012

Zynga (ZNGA) Reports Fourth Quarter and Full Year 2012 Financial Results

SAN FRANCISCO, Feb. 5, 2013 (GLOBE NEWSWIRE) — Zynga Inc. (Nasdaq:ZNGA), the world’s leading provider of social game services, today announced financial results for the fourth quarter and full year ended December 31, 2012.

  • Full year 2012 revenue of $1.28 billion, up 12% year-over-year, and bookings of $1.15 billion, down 1% year- over-year
  • Full year net loss of $209 million and adjusted EBITDA of $213 million
  • Full year 2012 GAAP EPS of ($0.28) and non-GAAP EPS of $0.07
  • Q4 revenue of $311 million, flat year-over-year, and bookings of $261 million, down 15% year-over-year
  • Q4 net loss of $48.6 million, down 89% year-over-year, adjusted EBITDA of $45 million, down 34% year-over- year
  • Q4 GAAP EPS of ($0.06) and non-GAAP EPS of $0.01

“The biggest highlight of the quarter was seeing our team deliver a successful sequel in FarmVille2, a next generation social game that offers cutting edge 3-D experiences loved by millions of FarmVille fans,” said Mark Pincus, CEO and Founder, Zynga. “In 2013 we’re excited to bring this new class of social games to mobile phones and tablets and build a network that offers an easier, better way for people to play together.”

Financial Highlights (in thousands, except per share data)

Quarter ended Year ended
GAAP Results Dec 31, 2012 Dec 31, 2011 Dec 31, 2012 Dec 31, 2011
Revenue $ 311,165 $ 311,237 $ 1,281,267 $ 1,140,100
Net loss $ (48,561) $ (435,005) $ (209,448) $ (404,316)
Diluted net loss per share $ (0.06) $ (1.22) $ (0.28) $ (1.40)
Non-GAAP Results
Bookings $ 261,269 $ 306,507 $ 1,147,627 $ 1,155,509
Adjusted EBITDA $ 45,018 $ 67,801 $ 213,233 $ 303,274
Non-GAAP net income $ 6,935 $ 37,153 $ 58,178 $ 182,483
Non-GAAP earnings per share $ 0.01 $ 0.05 $ 0.07 $ 0.24

Fourth Quarter 2012 Business Highlights

  • Daily active users (DAUs) increased from 54 million in the fourth quarter of 2011 to 56 million in the fourth quarter of 2012, up 3% year-over-year. On a consecutive quarter basis, DAUs were down 6% from 60 million in the third quarter of 2012.
  • Monthly active users (MAUs) increased from 240 million in the fourth quarter of 2011 to 298 million in the fourth quarter of 2012, up 24% year-over-year. On a consecutive quarter basis, MAUs were down 4% from 311 million in the third quarter of 2012.
  • Monthly unique users (MUUs) increased from 153 million in the fourth quarter of 2011 to 167 million in the fourth quarter of 2012, up 9% year-over-year. On a consecutive quarter basis, MUUs were down 6% from 177 million in the third quarter of 2012.
  • Average daily bookings per average DAU (ABPU) decreased from $0.061 in the fourth quarter of 2011 to $0.051 in the fourth quarter of 2012, down 17% year-over-year. On a consecutive quarter basis, ABPU was up 8% from $0.047 in the third quarter of 2012.
  • Monthly Unique Payers (MUPs) were 2.9 million in the fourth quarter of 2012, down 1% year-over-year and down 2% quarter-over-quarter.
  • Zynga released six new titles during the fourth quarter of 2012, including four new titles on web-based platforms: Bubble Safari Ocean, CityVille 2, CoasterVille and The Friend Game; and two new titles on mobile platforms: Ayakashi and Party Place. In addition, Zynga launched mobile versions of Bubble Safari and Ruby Blast.
  • As of December 31, 2012, Zynga had five of the top 10 games on Facebook, based on DAUs as reported by AppData, including some of its most established titles, Words With Friends and Zynga Poker, and some of its newer games, Bubble Safari, ChefVille and FarmVille 2.
  • In the fourth quarter of 2012, Zynga continued to expand its platform offering for third-party publishers, launching eight web games and four mobile games.
  • In December 2012, Zynga mobile game players in the US spent more time in Zynga games than the next five game companies combined, according to comScore.

“Our team executed well in the fourth quarter and made important progress in building sustainable new revenue streams and further aligning our company around our best growth opportunities,” said David Ko, Chief Operations Officer, Zynga. “2013 will be a pivotal transition year and we are focused on achieving three strategic objectives: growing our franchises on mobile and web, expanding our network and maintaining profitability on an adjusted EBITDA basis. With 298 million monthly average users, including 72 million on mobile alone, Zynga already has the largest social gaming audience and remains the best positioned company to lead in building the future of social gaming.”

2012 Annual Financial Summary

  • Revenue:Revenue was $1.28 billion in 2012, an increase of 12% on a year-over-year basis. Online game revenue was $1.14 billion, an increase of 7% on a year-over-year basis. Advertising revenue was $137 million, an increase of 84% on a year- over-year basis.
  • Bookings: Bookings were $1.15 billion in 2012, a decrease of 1% on a year-over-year basis.
  • Net loss: GAAP net loss was $209.4 million in 2012, which included $282.0 million of stock-based expense and $49.9 million of income tax expense driven by a $53.8 million charge related to accelerating the implementation of Zynga’s international structure.
  • Adjusted EBITDA: Adjusted EBITDA was $213.2 million in 2012, a decrease of 30% year-over-year, primarily due to increased cash investment in research and development, datacenters and infrastructure.
  • NonGAAP net income: Non-GAAP net income was $58.2 million in 2012, a decrease of 68% year-over-year, primarily due to increased investment in research and development.
  • EPS: Diluted EPS was ($0.28) for the full year 2012, compared to ($1.40) for the full year 2011.
  • NonGAAP EPS: Non-GAAP EPSwas $0.07 for the full year 2012, compared to $0.24 for the full year 2011.
  • Cash and Cash flow: As of December 31, 2012, cash, cash equivalents and marketable securities were approximately $1.65 billion, compared to $1.92 billion as of December 31, 2011. Cash flow from operations was $195.8 million for the year ended December 31, 2012, compared to $389.2 million for the year ended December 31, 2011. Free cash flow was ($114.3) million for the year ended December 31, 2012 as reported, or $119.4 million excluding the purchase of the company’s headquarters, compared to $137.3 million for the year ended December 31, 2011.

Fourth Quarter 2012 Financial Summary

  • Revenue:Revenue was $311.2 million for the fourth quarter of 2012, flat compared to the fourth quarter of 2011 and a decrease of 2% compared to the third quarter of 2012. Online game revenue was $274.3 million, a decrease of 3% compared to the fourth quarter of 2011 and a decrease of 4% compared to the third quarter of 2012. Advertising revenue was $36.8 million, an increase of 35% compared to the fourth quarter of 2011 and an increase of 19% compared to the third quarter of 2012.
  • Bookings: Bookings were $261.3 million for the fourth quarter of 2012, a decrease of 15% compared to the fourth quarter of 2011 and an increase of 2% compared to the third quarter of 2012.
  • Net loss: Net loss was $48.6 million for the fourth quarter of 2012 compared to a net loss of $435.0 million for the fourth quarter of 2011. Net loss for the fourth quarter of 2012 included $86.3 million of income tax expense driven by a $53.8 million charge related to accelerating the implementation of Zynga’s international structure and $14.9 million of stock- based expense compared to $530.0 million of stock-based expense included in the fourth quarter of 2011.
  • Adjusted EBITDA: Adjusted EBITDA was $45.0 million for the fourth quarter of 2012 compared to $67.8 million for the fourth quarter of 2011 and $16.2 million in the third quarter of 2012.
  • NonGAAP net income: Non-GAAP net income was $6.9 million for the fourth quarter of 2012, down from non-GAAP net income of $37.2 million in the fourth quarter of 2011 and up from a non-GAAP net loss of $0.4 million in the third quarter of 2012.
  • EPS: Diluted EPS was ($0.06) for the fourth quarter of 2012 compared to ($1.22) for the fourth quarter of 2011 and ($0.07) for the third quarter of 2012.
  • NonGAAP EPS: Non-GAAP EPS was $0.01 for the fourth quarter of 2012 compared to $0.05 for the fourth quarter of 2011 and $0.00 for the third quarter of 2012.
  • Cash and cash flow: As of December 31, 2012, cash, cash equivalents and marketable securities were approximately $1.65 billion, compared to $1.65 billion as of September 30, 2012. Cash flow from operations was $19.8 million for the fourth quarter of 2012, compared to $164.0 million for the fourth quarter of 2011. Free cash flow was $29.5 million for the fourth quarter of 2012 compared to $101.9 million for the fourth quarter of 2011.
  • Share Repurchase Program: As of December 31, 2012, Zynga repurchased approximately 5 million shares of common stock under its stock repurchase program. The remaining authorized amount of stock repurchases that may be made under this plan was approximately $188 million as of December 31, 2012.

Outlook

Zynga’s outlook for the first quarter of 2013 is as follows:

  • Revenue is projected to be in the range of $255 million to $265 million.
  • Net loss is projected to be in the range of ($32) million to ($12) million.
  • EPS is projected to be in the range of ($0.04) to ($0.02), based on a share count of approximately 780 million to 790 million shares.
  • Bookings are projected to be in the range of $200 million to $210 million.
  • Adjusted EBITDA is projected to be in the range of ($10) million to break even.
  • Non-GAAP EPS is projected to be in the range of ($0.05) to ($0.04), based on a share count of approximately 780 million to 790 million shares.

For full year 2013:

  • Zynga is targeting an adjusted EBITDA margin (adjusted EBITDA as a percentage of bookings) of 0% to 10%.

Conference Call Details:

Zynga will host a conference call today, February 5, 2013, at 2:00 pm Pacific Time (5:00 pm Eastern Time) to discuss financial results. A live webcast of the conference call and supplemental slides will be accessible from the Investor Relations page of the company’s website at http://investor.zynga.com and a replay will be archived and accessible at the same website after the call.

About Zynga Inc.

Zynga Inc. is the world’s leading provider of social game services, which include Zynga Poker, Words With Friends, Scramble With Friends, Gems with Friends, Draw Something, FarmVille, FarmVille2, ChefVille, CityVille, Bubble Safari and Ruby Blast. For the quarter ended December, 31, 2012, Zynga had approximately 298 million monthly active users playing its games. Zynga’s games are available on a number of global platforms, including Facebook, Zynga.com, Google+, Tencent, Apple iOS and Google Android. Zynga is headquartered in San Francisco, Calif.

The Zynga Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11743

Forward-Looking Statements

This press release contains forward-looking statements relating to, among other things, our outlook for first quarter 2013 revenue, net loss, EPS, weighted average diluted share count, bookings, adjusted EBITDA, non-GAAP net loss, non-GAAP EPS, non-GAAP weighted average diluted share count, stock-based expense and taxes; our outlook for full year 2013 capital expenditures, targeted adjusted EBITDA margin and taxes; our estimated pre-tax savings from our restructuring plans; our ability to remain profitable on an adjusted EBITDA basis; our future operational and strategic plans; expanding our network, including creating and building a mobile network and the success of that network; our ability to transition our web franchises to mobile and create new franchises on the web and mobile; our ability to launch successful games, including invest & express games, on mobile; our ability to launch successful new games and hit games for web and mobile generally; the success of our franchise games and our games and platform generally and the growth of the social games market, including the mobile market and the advertising market.  Forward-looking statements often include words such as “outlook,” “projected, ” “intends,” “will,” “anticipate,” “believe,” “target,” “expect,” and statements in the future tense are generally forward-looking statements. The achievement or success of the matters covered by such forward- looking statements involves significant risks, uncertainties and assumptions. Our actual results could differ materially from those predicted or implied, and reported results should not be considered as an indication of our future performance. Factors that could cause or contribute to such differences include, but are not limited to, our relationship with Facebook or changes in the Facebook platform, our ability to launch new games in a timely manner and monetize these games effectively on the web and on mobile, our ability to control and reduce expenses, our ability to anticipate and address technical challenges that may arise, competition, changing interests of players, intellectual property disputes or other litigation, asset impairment charges, our ability to retain key employees, acquisitions by us and changes in corporate strategy or management.

More information about factors that could affect our operating results is included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the three months ended September 30, 2012, in our registration statement on Form S-1, as amended, filed with the Securities and Exchange Commission on March 23, 2012 and in our Annual Report on Form 10-K for the year ended December 31, 2011, copies of which may be obtained by visiting our Investor Relations web site at http://investor.zynga.com or the SEC’s web site at www.sec.gov. Undue reliance should not be placed on the forward-looking statements in this release, which are based on information available to us on the date hereof. There is no guarantee that the circumstances described in our forward-looking statements will occur. We assume no obligation to update such statements. The results we report in our Annual Report on Form 10-K for the year ended December 31, 2012 could differ from the preliminary results we have announced in this press release.

DAU, MAU, MUU, MUP and ABPU figures presented in this press release represent the average for each period presented. The figures in this press release above represent the quarterly average of the three months within each quarter presented.

MUPs represents the aggregate number of unique players who made a payment at least once during the applicable month through a payment method for which we can quantify the number of unique payers. MUPs do not include payers who use certain payment methods for which we cannot quantify the number of unique payers. If a player made a payment in our games on two separate platforms (e.g. Facebook and Google+) in a month, the player would be counted as two unique payers in that month.

NonGAAP Financial Measures:

We have provided in this release non-GAAP financial information including bookings, adjusted EBITDA, non-GAAP net income, non-GAAP EPS, and free cash flow, as a supplement to the consolidated financial statements, which are prepared in accordance with generally accepted accounting principles (“GAAP”). Management uses these non-GAAP financial measures internally in analyzing our financial results to assess operational performance and liquidity. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because they allow for greater transparency with respect to key financial metrics we use in making operating decisions and because our investors and analysts use them to help assess the health of our business. We have provided reconciliations between our historical and first quarter 2013 outlook for non-GAAP financial measures to the most directly comparable GAAP financial measures. However, we have not provided reconciliation of our full year 2013 adjusted EBITDA margin (adjusted EBITDA as a percentage of bookings) outlook to a comparable operating income (loss) margin (operating income (loss) as a percentage of revenues) for full year 2013 because certain inputs necessary to accurately project revenue (including the projected mix of virtual goods sold in our games, the projected estimated average lives of durable virtual goods for our games and visibility into projected bookings) are not in our control and cannot be reasonably projected for the full year due to variability from period to period caused by changes in player behavior and other factors. As revenue is a necessary input to determine this comparable GAAP metric, we are not able to provide the reconciliation.

Some limitations of bookings, adjusted EBITDA, non-GAAP net income, non-GAAP EPS and free cash flow are:

  • Adjusted EBITDA and non-GAAP net income (loss) do not include the impact of stock-based expense and restructuring expense;
  • Bookings, adjusted EBITDA and non-GAAP net income (loss) do not reflect that we defer and recognize online game revenue and revenue from certain advertising transactions over the estimated average life of virtual goods or as virtual goods are consumed;
  • Adjusted EBITDA does not reflect income tax expense;
  • Adjusted EBITDA does not include other income and expense, which includes foreign exchange gains and losses, interest income; and the gain from the termination of our lease and purchase of our corporate headquarters building;
  • Adjusted EBITDA excludes both depreciation and amortization of intangible assets, while non-GAAP net income excludes amortization of intangible assets from acquisitions. Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future;
  • Adjusted EBITDA and non-GAAP net income (loss) do not include gains and losses associated with legal settlements;
  • Adjusted EBITDA and Non-GAAP net income (loss) do not include the impairment of intangible assets previously acquired in connection with the company’s purchase of OMGPOP.
  • Non-GAAP net income (loss) does not include the net gain from the termination of our lease and purchase of the Company’s corporate headquarters building;
  • Non-GAAP EPS treats shares of convertible preferred stock as if they had converted into common stock at the beginning of the applicable period presented;
  • Non-GAAP EPS gives effect to all dilutive awards based on the treasury stock method that were excluded from the GAAP diluted earnings per share calculation;
  • Free cash flow is derived from net cash provided by operating activities less cash spent on capital expenditures, including the purchase of our corporate headquarters building, and removing the excess income tax benefits or costs associated with stock-based awards; and
  • Other companies, including companies in our industry, may calculate bookings, adjusted EBITDA, non-GAAP net income (loss), non-GAAP EPS and free cash flow differently or not at all, which will reduce their usefulness as a comparative measure.

Because of these limitations, you should consider bookings, adjusted EBITDA, non-GAAP net income (loss), non-GAAP EPS and free cash flow, along with other financial performance measures, including revenue, net income (loss) and our other financial results presented in accordance with GAAP. See the GAAP to non-GAAP reconciliations below for further details.

ZYNGA INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, unaudited)
December 31, December 31,
2012 2011
Assets
Current assets:
Cash and cash equivalents $ 385,949 $ 1,582,343
Marketable securities 898,821 225,165
Accounts receivable 106,327 135,633
Income tax receivable 5,607 18,583
Deferred tax assets 30,122 23,515
Restricted cash 28,152 3,846
Other current assets 29,392 34,824
Total current assets 1,484,370 2,023,909
Long-term marketable securities 367,543 110,098
Goodwill 208,955 91,765
Other intangible assets, net 33,663 32,112
Property and equipment, net 466,074 246,740
Restricted cash 4,082
Other long-term assets 15,715 7,940
Total assets $ 2,576,320 $ 2,516,646
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable $ 23,298 $ 44,020
Other current liabilities 146,883 167,271
Deferred revenue 338,964 457,394
Total current liabilities 509,145 668,685
Long-term debt 100,000
Deferred revenue 8,041 23,251
Deferred tax liabilities 24,584 13,950
Other non-current liabilities 109,047 61,221
Total liabilities 750,817 767,107
Stockholders’ equity:
Common stock and additional paid-in capital 2,725,605 2,426,168
Treasury stock (295,113) (282,897)
Accumulated other comprehensive income (loss) (1,447) 362
Accumulated deficit (603,542) (394,094)
Total stockholders’ equity 1,825,503 1,749,539
Total liabilities and stockholders’ equity $ 2,576,320 $ 2,516,646
ZYNGA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data, unaudited)
Three Months Ended Twelve Months Ended
December 31, December 31,
2012 2011 2012 2011
Revenue:
Online game $ 274,337 $ 283,910 $  1,144,252 $  1,065,648
Advertising 36,828 27,327 137,015 74,452
Total revenue 311,165 311,237 1,281,267 1,140,100
Costs and expenses:
Cost of revenue 77,056 104,135 352,169 330,043
Research and development 131,847 444,702 645,648 727,018
Sales and marketing 32,446 112,228 181,924 234,199
General and administrative 32,206 136,733 189,004 254,456
Impairment of intangible assets 95,493
Total costs and expenses 273,555 797,798 1,464,238 1,545,716
Income (loss) from operations 37,610 (486,561) (182,971) (405,616)
Interest income 1,230 457 4,749 1,680
Other income (expense), net (1,111) (1,933) 18,647 (2,206)
Income (loss) before income taxes 37,729 (488,037) (159,575) (406,142)
(Provision for) benefit from income taxes (86,290) 53,032 (49,873) 1,826
Net loss $ (48,561) $  (435,005) $  (209,448) $  (404,316)
Net loss per share:
Basic and diluted $ (0.06) $ (1.22) $ (0.28) $ (1.40)
Weighted average common shares used to compute net loss per share:
Basic and diluted 771,533 356,305 741,177 288,599
Stock-based expense included in the above line items:
Cost of revenue $ 1,018 $ 16,058 $ 12,116 $ 17,660
Research and development 15,395 334,227 200,640 374,920
Sales and marketing 3,528 71,225 24,684 81,326
General and administrative (5,079) 108,461 44,546 126,306
Total stock-based expense $ 14,862 $ 529,971 $ 281,986 $ 600,212
ZYNGA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)
Three Months Ended Twelve Months Ended
December 31, December 31,
2012 2011 2012 2011
Operating activities
Net loss $ (48,561) $ (435,005) $ (209,448) $ (404,316)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization 33,430 31,266 141,479 95,414
Stock-based expense 14,862 529,971 281,986 600,212
Accretion and amortization on marketable securities 5,165 646 17,223 2,873
Net gain on termination of lease and purchase of building (19,886)
(Gain) loss from sales of investments, assets and other, net 724 830 563 (550)
Tax benefits from stock-based awards 15,972 21,652
Excess tax benefits from stock-based awards (15,972) 11,720 (21,652) 13,750
Deferred income taxes 14,550 4,367 (43,841) 4,367
Impairment of intangible assets 95,493
Changes in operating assets and liabilities:
Accounts receivable, net (726) (16,156) 34,338 (55,432)
Income tax receivable 1,157 (14,626) 12,976 17,994
Other assets 10,988 7,555 19,908 (14,559)
Accounts payable (14,272) (8,466) (21,312) 10,373
Deferred revenue (49,896) (4,730) (133,640) 15,409
Other liabilities 52,358 56,587 19,928 103,637
Net cash provided by operating activities 19,779 163,959 195,767 389,172
Investing activities
Purchase of marketable securities (298,815) (137,408) (1,826,137) (649,972)
Sales of marketable securities 73,711 6,586 223,828 19,206
Maturities of marketable securities 206,218 116,245 647,916 841,560
Acquisition of property and equipment (6,250) (50,355) (98,054) (238,091)
Purchase of building (233,700)
Business acquisitions, net of cash acquired (4,823) (205,510) (42,774)
Equity method investment (10,000) (10,000)
Restricted cash 443 16,878 6,979 9,194
Other investing activities, net 1 (2,256) (2,578)
Net cash used in investing activities (34,693) (52,876) (1,496,934) (63,455)
Financing activities
Proceeds from initial public offering, net of offering costs 961,402 961,402
Repurchase of common stock (11,756) (11,756) (283,770)
Proceeds from debt, net of issuance costs 99,780
Taxes paid related to net share settlement of equity awards (238) (83,232) (26,307) (83,232)
Proceeds from exercise of stock options and warrants 2,670 663 16,960 2,894
Proceeds from employee stock purchase plan 4,489
Excess tax benefits from stock-based awards 15,972 (11,720) 21,652 (13,750)
Net proceeds from issuance of preferred stock 485,300
Net cash provided by financing activities 6,648 867,113 104,818 1,068,844
Effect of exchange rate changes on cash and cash equivalents (144) (68) (45) (49)
Net increase (decrease) in cash and cash equivalents (8,410) 978,128 (1,196,394) 1,394,512
Cash and cash equivalents, beginning of period 394,359 604,215 1,582,343 187,831
Cash and cash equivalents, end of period $385,949 $1,582,343 $385,949 $1,582,343
ZYNGA INC.
RECONCILIATION OF GAAP TO NON-GAAP RESULTS
(In thousands, except per share data, unaudited)
Three months ended Twelve months ended
December 31, December 31,
2012 2011 2012 2011
Reconciliation of Revenue to Bookings
Revenue $311,165 $311,237 $1,281,267 $1,140,100
Change in deferred revenue (49,896) (4,730) (133,640) 15,409
Bookings $261,269 $306,507 $1,147,627 $1,155,509
Reconciliation of Net Loss to Adjusted EBITDA
Net loss $ (48,561) $ (435,005) $ (209,448) $ (404,316)
(Provision for) benefit from income taxes 86,290 (53,032) 49,873 (1,826)
Other income (expense), net 1,111 1,933 (18,647) 2,206
Interest income (1,230) (457) (4,749) (1,680)
Restructuring expense 7,862 7,862
Legal settlements 1,150 (2,145) 3,024 (2,145)
Depreciation and amortization 33,430 31,266 141,479 95,414
Impairment of intangible assets 95,493
Stock-based expense 14,862 529,971 281,986 600,212
Change in deferred revenue (49,896) (4,730) (133,640) 15,409
Adjusted EBITDA $45,018 $67,801 $213,233 $303,274
Reconciliation of Net Loss to Non-GAAP Net Income
Net loss $ (48,561) $ (435,005) $ (209,448) $ (404,316)
Impairment of intangible assets 95,493
Stock-based expense 14,862 529,971 281,986 600,212
Amortization of intangible assets from acquisitions 4,845 7,151 39,843 26,282
Change in deferred revenue (49,896) (4,730) (133,640) 15,409
Restructuring expense 7,862 7,862
Legal settlements 1,150 (2,145) 3,024 (2,145)
Gain on termination of lease and purchase of building (19,886)
Tax effect of non-GAAP adjustments to net loss 76,673 (58,089) (7,056) (52,959)
Non-GAAP net income $6,935 $37,153 $58,178 $182,483
Reconciliation of GAAP Diluted Shares to Non-GAAP
Diluted Shares
GAAP diluted shares 771,533 356,305 741,177 288,599
Assumed preferred stock conversion(1) 252,428 288,833
Other dilutive equity awards(2) 49,964 173,374 88,155 183,034
Non-GAAP diluted shares 821,497 782,107 829,332 760,466
Non-GAAP earnings per share $0.01 $0.05 $0.07 $0.24
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
Net cash provided by operating activities $19,779 $163,959 $195,767 $389,172
Acquisition of property and equipment (6,250) (50,355) (98,054) (238,091)
Purchase of building (233,700)
Excess tax benefits from stock-based awards 15,972 (11,720) 21,652 (13,750)
Free cash flow $ 29,501 $ 101,884 $ (114,335) $ 137,331
(1) Gives effect to the conversion of convertible preferred stock into common stock as though the conversion had occurred at the beginning of the period.
(2) Gives effect to all dilutive awards based on the treasury stock method.
ZYNGA INC.
RECONCILIATION OF GAAP TO NON-GAAP FIRST QUARTER 2013 OUTLOOK
(In thousands, except per share data, unaudited)
First Quarter 2013
Reconciliation of Revenue to Bookings
Revenue range $ 255,000 – 265,000
Change in deferred revenue (55,000)
Bookings range $ 200,000 210,000
Reconciliation of Net Loss to Adjusted EBITDA
Net loss range $ (32,000) – (12,000)
Benefit from income taxes (3,000)
Other expense, net 1,000
Interest income (1,000)
Restructuring expense 2,000
Depreciation and amortization 33,000
Stock-based expense range 45,000 – 35,000
Change in deferred revenue (55,000)
Adjusted EBITDA range $ (10,000) 0
Reconciliation of Net Loss to Non-GAAP Net
Loss
Net loss range $ (32,000) – (12,000)
Stock-based expense range 45,000 – 35,000
Amortization of intangible assets from acquisitions 3,500
Change in deferred revenue (55,000)
Restructuring expense 2,000
Tax effect of non-GAAP adjustments to net loss (4,000)
Non-GAAP net loss range $ (40,500) – (30,500)
GAAP and Non-GAAP diluted shares 780,000 – 790,000
Net loss per share range $ (0.04) – (0.02)
Non-GAAP net loss per share range $ (0.05) – (0.04)
CONTACT: Investors - Krista Bessinger
         415-339-5266
         investors@zynga.com

         Press - Stephanie Hess
         415-503-0303
         press@zynga.com

Zynga Inc. Logo

Tuesday, February 5th, 2013 Uncategorized Comments Off on Zynga (ZNGA) Reports Fourth Quarter and Full Year 2012 Financial Results

Cache (CACH) Announces CEO Succession

Cache, Inc., (NASDAQ: CACH), a specialty chain of women’s apparel stores, announced today that its Board of Directors appointed Jay Margolis as Chairman and Chief Executive Officer of Cache. Concurrent with this appointment, Thomas Reinckens will step down as Chairman of the Board and Chief Executive Officer of Cache.

Mr. Margolis is a highly accomplished executive with over 30 years of retail, merchandising and product development experience in the specialty retail industry. He has held senior leadership positions with several high profile retail and apparel companies, most recently serving as President and Chief Executive Officer of Limited Brands’ Apparel Group (Express and Limited Stores), where he was responsible for revamping the product line and leading the successful operational turnaround of the businesses. Prior to Limited Brands, Mr. Margolis was President, Chief Operating Officer & Director of Reebok International, where he played a critical role in improving the financial and operating performance of the Reebok, Rockport and Ralph Lauren Footwear brands. Prior to Reebok, Mr. Margolis served as Chairman and CEO of Esprit de Corporation, USA, President and Vice Chairman of the Board of Directors of Tommy Hilfiger Inc. and in several senior executive positions at Liz Claiborne Inc. Mr. Margolis currently sits on the Board of Directors of Burlington Coat Factory Warehouse Corporation, Godiva Chocolatier Inc. and Boston Beer Company.

Mr. Reinckens, outgoing Chairman and Chief Executive Officer, commented: “We are excited to attract a leader of Jay’s caliber to the position of Chairman and CEO of Cache. Jay is a highly accomplished merchant with proven success in strengthening assortments, growing revenues, increasing store productivity and driving product sales in new channels, all of which is expected to position our Company for sustained long term profitability and growth. We are confident that Jay is the perfect choice for this important role.”

“I have spent much of my career at Cache and it has been an honor to be part of this organization, leading the Company as Chairman and CEO for the past four years and prior to that working as Chief Financial Officer,” Mr. Reinckens continued. “I want to thank our employees, vendor partners and the Cache Board of Directors for their support over the past 25 years.”

Mr. Margolis stated, “I am delighted to be joining Cache and believe a there is a significant opportunity to build upon the existing foundation and create a great retail brand. Cache is a unique brand that has a loyal customer base, and I look forward to developing and executing a business plan that will allow the Company to return to profitability and growth.”

In conjunction with joining the Company Mr. Margolis will invest $1 million in newly issued shares of Cache in connection with the $8.0 million Rights Offering announced today by the Company, subject to shareholder approval. The proceeds of the Rights Offering will be used to provide enhanced liquidity to Cache.

In connection with the Rights Offering, the Company announced that it entered into an Investment Agreement with Mr. Margolis and two of the Company’s shareholders, MFP Partners, L.P. and Mill Road Capital, L.P., under which they have each agreed to backstop the Rights Offering on the terms and subject to the conditions contained in that agreement (the “Backstop and Investment Agreement”). The Rights Offering will provide the opportunity for all Cache shareholders to invest at the same price as Mr. Margolis, MFP Partners and Mill Road. Pursuant to the Rights Offering, each Cache shareholder will be issued transferable rights that will enable the holder to purchase, at $1.65 per share, one share of Common Stock for each whole right. Holders of rights who fully exercise all of their rights will also be entitled, to the extent the Rights Offering is not fully subscribed, to purchase additional shares of Common Stock for $1.65 per share (up to the number of shares purchased under the holder’s basic subscription privilege). Under the Backstop and Investment Agreement, MFP Partners and Mill Road have each agreed to purchase a number of shares equal to their pro rata portion of the shares offered in the Rights Offering, and, together with Mr. Margolis, they have each agreed to backstop the Rights Offering such that Cache will receive the full $8 million. Cache will seek to list the rights on the Nasdaq Global Select Market.

Pursuant to the Backstop and Investment Agreement, Mr. Margolis and Mill Road have been granted the right to purchase additional shares of Common Stock from the Company for $1.65 per share in an amount sufficient to enable them to acquire $1.0 million and $3.5 million of Common Stock, respectively, to the extent that they are not able to acquire those amounts through the Rights Offering and the backstop. The Company expects to commence the Rights Offering as soon as practicable, and has not yet determined the record date, anticipated issuance date, or expiration date in respect of the Rights Offering. The Backstop and Investment Agreement is subject to satisfaction of customary conditions, including shareholder approval of the issuance of the shares thereunder. Financo LLC. is serving as the exclusive financial advisor to Cache in this transaction. Schulte Roth & Zabel LLP served as counsel to Cache in connection with the transactions described herein. Skadden, Arps, Slate, Meagher & Flom LLP and Foley Hoag LLP represented MFP and Mill Road, respectively.

The Company also announced today that it entered into a Voting Agreement with MFP Partners and Mill Road providing that Michael F. Price and an independent individual designated by Mill Road will be appointed to serve as directors of the Company on the day prior to the shareholders meeting to vote on the issuance of shares in the Rights Offering and under the Backstop and Investment Agreement (or such later date designated by them). In addition, the Voting Agreement provides, among other things, that at the Company’s 2013 annual meeting of shareholders, such individuals, and an additional individual designated by MFP Partners, will be nominated for election to the Board and each of MFP Partners and Mill Road will vote all of their shares of Common Stock in favor of the election of such individuals to the Board, in each case, subject to the terms of the Voting Agreement. The term of the Voting Agreement expires immediately following the 2013 annual meeting of shareholders, unless earlier terminated in accordance with its terms.

Separately, Cache announced preliminary unaudited results for the 13-week period ended December 29, 2012:

For the fourth quarter of 2012, the 13-week period ended December 29, 2012:

  • Net sales are expected to decrease 3.3% to 60.8 million, compared to $62.9 million in the fourth quarter of 2011;
  • Comparable store sales are expected to decline 0.7%, compared to the 12.4% increase in the fourth quarter of 2011; and
  • Pre-tax loss is currently expected in the range $4.8 – $5.1 million, compared to pretax income of $2.4 million in the fourth quarter of 2011.

In addition:

  • Inventory at year end is expected to decline modestly from the prior year end; and
  • Cash and marketable securities at year end are expected to decline to approximately $18 million from $26.5 million at the prior year end.

The foregoing results are preliminary in nature and remain subject to finalization. Actual results may differ, and any such difference could be material.

This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of any securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. The Rights Offering will be made only by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

About Cache, Inc.

Cache is a nationwide, mall-based specialty retailer of sophisticated sportswear and social occasion dresses targeting style-conscious women who have a youthful attitude and are self-confident. The Company currently operates 261 stores, primarily situated in central locations in high traffic, upscale malls in 42 states, the Virgin Islands and Puerto Rico.

Certain matters discussed within this press release may constitute forward-looking statements within the meaning of the federal securities laws. Although Cache, Inc. believes the statements are based on reasonable assumptions, there can be no assurance that these expectations will be attained. Actual results and timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors, including, without limitation, satisfaction of the conditions relating to the Rights Offering and the other transactions contemplated by the Backstop and Investment Agreement, industry trends, merchandise and fashion trends, competition, seasonality and changes in general economic conditions and consumer spending patterns, reliance on foreign manufacturers, dependence on management, dependence on vendors and distributors, material weakness in our internal controls, as well as other risks outlined from time to time in the filings of Cache, Inc. with the Securities and Exchange Commission.

Tuesday, February 5th, 2013 Uncategorized Comments Off on Cache (CACH) Announces CEO Succession

Merck Serono and Opexa (OPXA) Option/License Agreement Over MS Drug Tcelna™

  • Merck Serono granted option for exclusive license from Opexa to develop and commercialize Tcelna (imilecleucel-T), an investigational T-cell therapy for patients suffering from multiple sclerosis (MS).

Merck Serono, a division of Merck, Darmstadt, Germany, today announced the execution of an agreement with Opexa Therapeutics, Inc (NASDAQ:OPXA) for the development and commercialization of Tcelna(imilecleucel-T), a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis (MS). Tcelna (imilecleucel-T) is being developed by Opexa and currently is in a Phase IIb clinical trial in patients with Secondary Progressive MS (SPMS).

Tcelna (imilecleucel-T) is being developed as a personalized therapy specifically tailored to each patient’s individual disease profile and has been evaluated in Phase I and II clinical studies in MS that included SPMS patients. Tcelna (imilecleucel-T) has received Fast Track Designation from the United States Food and Drug Administration as a potential treatment for SPMS.

Under the terms of the agreement, Opexa will receive an upfront payment of $5 million for granting an option to Merck Serono for the exclusive license of the Tcelna (imilecleucel-T) program for the treatment of MS. The option may be exercised prior to or upon completion of Opexa’s ongoing Phase IIb clinical trial in patients with SPMS. Upon exercising this licensing option, Merck Serono would pay an upfront license fee, and in return receive worldwide development and commercial rights to Tcelna (imilecleucel-T) in MS, excluding Japan. After exercising the option, Merck Serono would be wholly responsible for funding clinical development, subject to Opexa’s co-funding option, as well as regulatory and commercialization activities for the MS program.

Under the agreement, Opexa will have an option right to co-fund development, under which the Company would participate in economic support for future clinical development of the program in exchange for additional royalty consideration.  In addition to retaining all rights outside of MS as well as retaining the ability to commercialize Tcelna (imilecleucel-T) in Japan, Opexa also retains certain manufacturing rights related to the program.

“Merck Serono is strongly committed to developing innovative drug candidates like Tcelna (imilecleucel-T), a potential first-in-class personalized cell therapy for patients with multiple sclerosis,” said Susan Herbert, Head of Global Business Development and Strategy at Merck Serono. “This agreement illustrates Merck Serono’s commitment to employ creative ways of accessing external innovation to develop potential next generation multiple sclerosis treatments, especially in secondary progressive multiple sclerosis, an area of high unmet need.”

Neil K. Warma, President and Chief Executive Officer of Opexa, commented: “Opexa is pleased to partner with Merck Serono and given Merck Serono’s long-term strategic commitment to, and existing franchise position in the field of multiple sclerosis, we could not ask for a more experienced partner to carry Tcelna (imilecleucel-T)  through development and hopefully to the market and to patients. We also are pleased to retain important rights through this transaction, such as certain manufacturing rights, commercialization rights to the Japanese market and a co-funding of development option, as well as rights for all indications outside of MS, all of which are intended to enhance Opexa shareholder value.”

About Multiple Sclerosis (MS)

MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.

While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Tcelna (imilecleucel-T)

Tcelna (imilecleucel-T) is a potential personalized therapy that is under development to be specifically tailored to each patient’s disease profile. Tcelna (imilecleucel-T) is manufactured using ImmPath, Opexa’s proprietary method for the production of a patient-specific T-cell immunotherapy, which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response.

Opexa is currently conducting a Phase IIb study of Tcelna (imilecleucel-T). Named Abili-T, the trial is a randomized, double-blind, placebo-controlled clinical study in patients who demonstrate evidence of disease progression without associated relapses. The trial is expected to enroll 180 patients at approximately 30 leading clinical sites in the U.S. and Canada with each patient receiving two annual courses of Tcelna (imilecleucel-T) treatment consisting of five subcutaneous injections per year. The trial’s primary efficacy outcome is the percentage of brain volume change (atrophy) at 24 months. Study investigators will also measure several important secondary outcomes commonly associated with MS, including disease progression as measured by the Expanded Disability Status Scale (EDSS), annualized relapse rate and changes in disability as measured by EDSS and the MS Functional Composite.

About Opexa

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as MS. The Company’s leading therapy candidate, Tcelna (imilecleucel-T), is a personalized cellular immunotherapy that is in phase IIb clinical development for MS. Tcelna (imilecleucel-T) is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.

For more information visit the Opexa Therapeutics website at http://www.opexatherapeutics.com

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of oncology, neurology and immunology.

For more information, please visit http://www.merckserono.com or http://www.merckgroup.com

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of €10.3 billion in 2011, a history that began in 1668, and a future shaped by approx. 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit http://www.merckserono.com or http://www.merckgroup.com

Tuesday, February 5th, 2013 Uncategorized Comments Off on Merck Serono and Opexa (OPXA) Option/License Agreement Over MS Drug Tcelna™

Commtouch (CTCH) Named Finalist in Five Categories of Info Security Products Guide Awards

Winners to be announced in San Francisco on February 27 during awards dinner

MCLEAN, Virginia, February 4, 2013 /PRNewswire/ —

Commtouch® (NASDAQ: CTCH), a leading provider of Internet security technology and cloud-based services, today announced that Info Security Products Guide, the industry’s leading information security research and advisory guide, has named Commtouch a finalist for the 2013 Global Excellence Awards in five categories:

  • Anti-Malware, Anti-Spam or Antivirus (Commtouch Messaging Security Service)
  • Email Security and Management (Commtouch Messaging Security Service)
  • Social Media, Web Filtering, and Content Security (Commtouch GlobalView™ URL Filtering)
  • Tomorrow’s Technology Today (Upcoming Commtouch Advanced Persistent Threat Detection)
  • Best Overall Security Company of the Year

“We are honored that Info Security Products Guide has recognized Commtouch’s messaging and URL filtering services as technological leaders in the industry,” said Shlomi Yanai, CEO at Commtouch. “Through constant innovation and a focus on easily deployed cloud-based OEM security solutions, Commtouch technology protects thousands of organizations and hundreds of millions of users worldwide. We believe this recognition from Info Security Products Guide further validates our commitment to our customers and their security needs.”

(Logo: http://photos.prnewswire.com/prnh/20120501/529254 )

The prestigious global awards recognize security and IT vendors with advanced, ground-breaking products and solutions that are helping set the bar higher for others in all areas of security and technologies. The winners will be announced and honored at the annual Info Security Products Guide awards dinner in San Francisco on February 27, 2013.

About Commtouch Messaging Security Service

With an average of more than 87 billion spam messages emailed each day, organizations face ever-increasing security costs and the constant challenge of maintaining performance for valid email traffic.  The Commtouch Messaging Security Service offers service providers and security companies the ability to combat spam at the perimeter and reduce the number of incoming messages by more than 85 percent before they ever enter the network.

About Commtouch’s GlobalView URL Filtering

The Commtouch GlobalView URL Filtering solution leverages a unique “in the cloud” infrastructure to provide unprecedented breadth of Web coverage that remains unmatched in the industry. It localizes responses specifically to the needs of end-customers, avoiding the “one size fits all” approach of traditional solutions.

About Upcoming Commtouch Advanced Persistent Threat (APT) Detection

Currently in its research and development phase, the Commtouch APT Detection Service will be specifically designed to supplement and enhance gateway security solutions including firewalls, secure Web gateways, UTMs and IDS/IPS solutions. It will detect hosts infected with malicious programs and prevent the extraction of sensitive information and abuse of organizational resources.

About Info Security Products Guide Awards

SVUS Awards organized by Silicon Valley Communications are conferred in four annual award programs: The Info Security’s Global Excellence Awards, The IT Industry’s Hot Companies and Best Products Awards, The Golden Bridge Business and Innovation Awards, and Consumer Products Guide’s Best Choice Awards. These premier awards honor organizations of all types and sizes from all over the world including people behind them, the products, performance, PR and marketing. To learn more, visit http://www.svusawards.com.

About Commtouch

Commtouch® (NASDAQ: CTCH) is a leading provider of Internet security technology and cloud-based services for vendors and service providers, increasing the value and profitability of customers’ solutions by protecting billions of Internet transactions on a daily basis. With six global data centers and renowned technology, Commtouch’s email, Web, and antivirus capabilities easily integrate into customers’ products and solutions, keeping more than 350 million end users safe. To learn more, visit http://www.commtouch.com.

  • Blog: http://blog.commtouch.com/cafe
  • Facebook: http://www.facebook.com/commtouch
  • LinkedIn: http://www.linkedin.com/company/commtouch
  • Twitter: @Commtouch

Recurrent Pattern Detection, RPD, Zero-Hour and GlobalView are trademarks, and Commtouch is a registered trademark of Commtouch. U.S. Patent No. 6,330,590 is owned by Commtouch. All other trademarks are the property of their respective owners.

Company Contact:
Brian Briggs, Chief Financial Officer
Commtouch
+1-703-760-3444
brian.briggs@commtouch.com

U.S. Investor Contact:
Christopher Chu
Grayling
+1-646-284-9400
commtouch@grayling.com

Israel Investor Relations Contact:
Iris Lubitch
EffectiveIR
+972-54-252-8007
Iris@EffectiveIR.co.il

Commtouch Media Contact:
Matthew Zintel
Zintel Public Relations
+1-281-444-1590
matthew.zintel@zintelpr.com

Monday, February 4th, 2013 Uncategorized Comments Off on Commtouch (CTCH) Named Finalist in Five Categories of Info Security Products Guide Awards

Constellation Energy Partners (CEP) to Sell Alabama Assets

Constellation Energy Partners LLC (NYSE MKT: CEP) today announced that it has executed a definitive agreement to sell its Robinson’s Bend Field assets and operations, which are located in the Black Warrior Basin in Tuscaloosa County, Alabama, to a subsidiary of Castleton Commodities International LLC (“CCI”).

The sale encompasses over 500 operating natural gas wells in the Robinson’s Bend Field together with related leasehold interests and infrastructure.

The transaction is expected to close in the first quarter 2013 and will have an effective date of December 1, 2012. The company anticipates that net proceeds received in the transaction will be used to reduce outstanding debt.

Lantana Oil & Gas Partners, Inc. was divestment advisor to CEP for the sales process. Stifel provided a fairness opinion to the company’s board of managers in connection with the transaction.

Additional details concerning the sale of the company’s Robinson’s Bend assets can be found in the company’s filings with the Securities and Exchange Commission and on the company’s Web site (http://www.constellationenergypartners.com).

About the Company

Constellation Energy Partners LLC is a limited liability company focused on the acquisition, development and production of oil and natural gas properties, as well as related midstream assets.

About CCI

CCI (formerly Louis Dreyfus Highbridge Energy) is a global commodities merchant with an integrated set of operations consisting of the marketing and merchandising of commodities and the ownership, operations, and development of commodities-related upstream and infrastructure assets. The Company markets a broad range of physical commodities including natural gas, natural gas liquids, refined products, crude oil, fuel oil, freight, petrochemicals, electric power and coal and financial instruments related to commodities. CCI is headquartered in Stamford, Connecticut, with offices in Houston, Texas; Denver, Colorado, Calgary, Canada; Lausanne, Switzerland; Shanghai, China; Singapore; and Uruguay.

Forward-Looking Statements

We make statements in this news release that are considered forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. These forward-looking statements are largely based on our expectations, which reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently known market conditions and other factors. Although we believe such estimates and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond our control. In addition, management’s assumptions about future events may prove to be inaccurate. Management cautions all readers that the forward-looking statements contained in this news release are not guarantees of future performance, and we cannot assure you that such statements will be realized or the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied in the forward-looking statements due to factors listed in the “Risk Factors” section in our SEC filings and elsewhere in those filings. All forward-looking statements speak only as of the date of this news release. We do not intend to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise. These cautionary statements qualify all forward-looking statements attributable to us or persons acting on our behalf.

Monday, February 4th, 2013 Uncategorized Comments Off on Constellation Energy Partners (CEP) to Sell Alabama Assets

Horizon Pharma (HZNP) to Present at the 15th Annual BIO CEO and Investor Conference

DEERFIELD, IL — (Marketwire) — 02/04/13 — Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, is scheduled to present at the 15th Annual BIO CEO and Investor Conference on Monday, February 11, 2013 at 4:30pm Eastern Time in New York, NY. Mr. Walbert will provide an overview of the Company and its corporate activities.

The presentation will be webcast live and may be accessed by visiting Horizon’s website at http://ir.horizon-pharma.com. A replay of the webcast will be available for 10 business days.

About Horizon Pharma
Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. For more information, please visit www.horizonpharma.com.

Contacts
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Email Contact

Investors
Kathy Galante
Burns McClellan, Inc.
212-213-0006
Email Contact

Monday, February 4th, 2013 Uncategorized Comments Off on Horizon Pharma (HZNP) to Present at the 15th Annual BIO CEO and Investor Conference

Magellan (MPET) Regains Compliance with NASDAQ Listing

DENVER, Feb. 4, 2013 /PRNewswire/ — On February 1, 2013, Magellan Petroleum Corporation (“Magellan” or the “Company”) (NASDAQ: MPET) (ASX: MGN) received formal notification from the NASDAQ Stock Market LLC (“NASDAQ”) that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company to maintain a minimum closing bid price of $1.00 per share.  NASDAQ staff made this determination of compliance after the Company’s bid price closed above $1.00 per share for the prior 10 consecutive business days.

NASDAQ had previously notified the Company of its non-compliance with Listing Rule 5550(a)(2) on November 19, 2012, following 30 consecutive business days for which the Company’s closing bid price did not meet the $1.00 per share minimum requirement.

Tom Wilson, President and CEO of Magellan, stated, “Over the past year, we have simplified our story, focused our operational strategy, and revamped our investor communications.  Regaining compliance with NASDAQ is a validation of these efforts and a sign that the market is beginning to see the inherent value of our assets.”

CAUTIONARY INFORMATION ABOUT FORWARD LOOKING STATEMENTS
Statements in this release that are not historical in nature are intended to be, and are hereby identified as, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  These statements about Magellan may relate to its businesses, prospects, and other matters that involve a number of risks and uncertainties that may cause actual results to differ materially from the results expressed or implied in the forward-looking statements.  Among these risks and uncertainties are those set forth in the Risk Factors sections of Magellan’s most recent 10-K and subsequent 10-Qs filed with the SEC.

ABOUT MAGELLAN
Magellan is an independent energy company engaged in the exploration, development, production, and sale of crude oil and natural gas from currently held assets in the United States, Australia, and the United Kingdom.  Traded on NASDAQ since 1972, the Company conducts its operations through two wholly owned subsidiaries, Nautilus Poplar LLC, which owns interests at Poplar, a highly attractive oil field in the Williston Basin, and Magellan Petroleum Australia Limited, a successful independent oil and gas company in Australia and the UK in existence since 1964.  The Company’s mission is to enhance shareholder value by maximizing the full potential of existing assets.  Magellan routinely posts important information about the Company on its website at www.magellanpetroleum.com.

For further information, please contact:
Matthew Ciardiello, Manager, Investor Relations at 720.484.2404

Monday, February 4th, 2013 Uncategorized Comments Off on Magellan (MPET) Regains Compliance with NASDAQ Listing

Manhattan Bridge (LOAN) Increases Its Revolving Line of Credit to $5 Million

LONG ISLAND, N.Y., Feb. 4, 2013 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (Nasdaq:LOAN) announced today that its Revolving Line of Credit with Sterling National Bank was increased to up to $5 million, $1.5 million more than the previous limit. The terms of the increased line are similar to the terms of the original line established on May 2, 2012.

Assaf Ran, Chairman of the Board and CEO stated, “This increase is excellent news for the Company. It will allow us to continue our solid and consistent growth.”

This report contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are typically identified by the words “believe,” “expect,” “intend,” “estimate” and similar expressions. Those statements appear in a number of places in this report and include statements regarding our intent, belief or current expectations or those of our directors or officers with respect to, among other things, trends affecting our financial conditions and results of operations and our business and growth strategies. These forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors (such factors are referred to herein as “Cautionary Statements”), including but not limited to the following: (i) the successful integration of new businesses that we may acquire; (ii) the success of new operations which we have commenced and of our new business strategy; (iii) our limited operating history in our new business; (iv) potential fluctuations in our quarterly operating results; and (v) challenges facing us relating to our growth. The accompanying information contained in this report, including the information set forth under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, identifies important factors that could cause such differences. These forward-looking statements speak only as of the date of this report, and we caution potential investors not to place undue reliance on such statements. We undertake no obligation to update or revise any forward-looking statements. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the Cautionary Statements.

CONTACT: Assaf Ran, CEO
         (516) 444-3400
Monday, February 4th, 2013 Uncategorized Comments Off on Manhattan Bridge (LOAN) Increases Its Revolving Line of Credit to $5 Million

Venaxis, Inc. (APPY) to Webcast Live at RetailInvestorConferences.com

Company Invites Main Street and Wall Street Investors to Attend Interactive Real-time Virtual Conference

CASTLE ROCK, Colo., Feb. 4, 2013 /PRNewswire/ — Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that Steve Lundy, President and Chief Executive Officer, will present at RetailInvestorConferences.com.

DATE:

February 7, 2013

TIME:

10:00 AM EST

LINK:

www.retailinvestorconferences.com > Click red “register / watch event now” button

This will be a live, interactive online event where investors are invited to ask the company questions in real-time, both in the presentation hall as well as the company’s “virtual trade booth.”  If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About Venaxis, Inc.

Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1.  The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.venaxis.com.

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire’s leading-edge online conferencing and investor communications capabilities with BetterInvesting’s extensive retail investor audience network.

Forward-Looking Statements

This press release includes “forward-looking statements” of Venaxis, Inc. (“Venaxis”) (formerly AspenBio Pharma, Inc.) as defined by the Securities and Exchange Commission (“SEC”). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, complete and maintain CE Marking, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company’s objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis’ recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

Monday, February 4th, 2013 Uncategorized Comments Off on Venaxis, Inc. (APPY) to Webcast Live at RetailInvestorConferences.com

Cardiome (CRME) Selects Quintiles To Manage Global Regulatory Affairs

VANCOUVER, Feb. 4, 2013 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the selection of Quintiles to provide comprehensive post-marketing lifecycle safety and global regulatory affairs services for BRINAVESS™. Quintiles, the world’s leading provider of biopharmaceutical services, will begin providing these services effective immediately as Cardiome continues to prepare for the anticipated transfer of BRINAVESSTM from Merck to Cardiome.

“We are very pleased to begin our partnership with Quintiles during the pending return of global rights for the intravenous (IV) and oral formulations of vernakalant to Cardiome,” stated William Hunter, M.D., interim CEO of Cardiome. “Finding a highly capable service provider to deliver operational regulatory and pharmacovigilance support was a key priority to effectively and expeditiously transfer the registered marketing authorizations from Merck to Cardiome.  We believe that Quintiles’ global reach and extensive expertise in these areas will help facilitate a seamless worldwide transition.”

In September 2012, Merck informed Cardiome that Merck (through two of its subsidiaries) would return the global marketing and development rights for both the intravenous and oral formulations of vernakalant to Cardiome. Vernakalant IV is marketed under the brand name BRINAVESSTM. BRINAVESSTM has received approval in the European Union and certain other markets worldwide for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults: for non-surgery patients with AF of seven days or less and for post-cardiac surgery patients with AF of three days or less. Vernakalant IV is not approved for use in the United States or Canada.

About Cardiome Pharma Corp. Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Risks, uncertainties and factors that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks, uncertainties and factors related to the fact that: we, together with our collaborative partner, may not be able to successfully develop all or any of our current or future products and may not be able to obtain regulatory approval in targeted indications for our current or future products in all markets; we may not achieve or maintain profitability; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital as and when required; we depend on our collaborative partner to perform their obligations under licensing or other collaborative agreements; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; any of our products that obtain regulatory approval will be subject to extensive post-market regulation that may affect sales, marketing and profitability; any of our products that are successfully developed may not achieve market acceptance; we rely on third parties for the continued supply and manufacture of our products and have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters, including with respect to our ability to protect our intellectual property; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com.  Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Monday, February 4th, 2013 Uncategorized Comments Off on Cardiome (CRME) Selects Quintiles To Manage Global Regulatory Affairs